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2 Summary 
The calcineurin-NFAT signaling axis is of major importance for the pathological remodeling of 
the heart as well as for the signal transduction in cardiomyocytes in general. The aim of this 
study was to systematically identify yet unknown activators of the calcineurin-NFAT signaling 
pathway. Therefore a human cardiac cDNA library with approximately 107 primary clones was 
utilized and investigated with the help of an NFAT-driven firefly reporter cell line (C2C12 mouse 
myoblasts). Several steps of dilutions and sub-dilutions of the clones, followed by verifications 
and validations of the preliminary findings from this screen led to the identification of SUMO2 
as a robust activator of calcineurin-NFAT signaling. Moreover, data from the present study 
revealed that SUMO2 activates NFAT signaling via direct interaction with calcineurin A (CnA), 
endogenously. Further experiments showed that SUMO2 activates NFAT signaling directly via 
calcineurin A (CnA). This is supported by the finding that the presence of constitutively active 
calcineurin A (ΔCnA) in addition to SUMO2 further exaggerates the activation of NFAT 
signaling. Additionally, wildtype calcineurin A enhanced the SUMO2 mediated NFAT activation 
further upon activation by Ionomycin/PMA-treatment of the cells. A siRNA mediated 
knockdown of SUMO2 reduced the NFAT activation. The results obtained from overexpression 
and knockdown experiments in mouse myoblasts could be reproduced in neonatal rat 
ventricular cardiomyocytes (NRVCM). Subsequently, the molecular and phenotypical effects 
of SUMO2 were characterized in NRVCM. SUMO2 induced hypertrophy in NRVCM that could 
be further enhanced in the presence of ΔCnA. The SUMO2 induced hypertrophy could be 
abrogated by pharmacological inhibition of calcineurin A by Ciclosporin or Tacrolimus. 
Surprisingly, a sumoylation-deficient mutant of SUMO2 (SUMO2ΔGG) resembled the effects 
of the sumoylation-capable SUMO2 in almost all parameters investigated, suggesting a 
mechanism that is independent of a covalent attachment of SUMO2. Mechanistically, it could 
be shown that in experiments with overexpression of ΔCnA together with SUMO2 or 
SUMO2ΔGG, calcineurin displayed an enhanced nuclear localization, whereas this effect 
could not be observed with only ΔCnA overexpression. 
Concluding from these findings, SUMO2 was identified as a new, positive modulator of the 
calcineurin-NFAT signaling pathway. Interestingly, these effects seem to be sumoylation-
independent and suggest a nuclear retention of activated calcineurin.
  
   
Zusammenfassung 
 
 
 
 
   10  
  
 
3 Zusammenfassung 
Der Calcineurin-NFAT Signalweg ist von entscheidender Bedeutung für die Entwicklung 
pathologischer Veränderungen am Herzen, sowie auch allgemein für die Signaltransduktion in 
Kardiomyozyten. Ziel dieser Studie war es, systematisch unbekannte Modulatoren des 
Calcineurin-NFAT Signalwegs zu identifizieren. Dafür wurde eine humane, kardiale cDNA-
Bibliothek (107 Primärklone) mithilfe von NFAT-Luziferase-Reporter Zellen (C2C12, murine 
Muskelzellen) untersucht. Nach mehreren Runden der Verifizierung konnten wir SUMO2 als 
neuen und starken Aktivator des Calcineurin-NFAT Signalwegs identifizieren. Darüber hinaus 
fanden wir heraus, dass SUMO2 ein direkter Interaktionspartner mit einem nukleären 
Calcineurin A-Pool ist. Weitergehende Experimente in C2C12-Zellen zeigten, dass SUMO2 
die NFAT-Signaltransduktion mittels Calcineurin A induziert. Dafür spricht, dass selbst in 
Anwesenheit von konstitutiv aktivem CnA (ΔCnA), die NFAT-Aktivierung durch SUMO2 
steigerbar ist. Ebenfalls wurde Wildtyp-Calcineurin, zusätzlich zur Aktivierung durch 
Ionomycin/PMA-behandlung, verstärkt in Anwesenheit von SUMO2 aktiviert. Eine siRNA-
vermittelte Herunterregulierung von SUMO2 reduziert die NFAT-Aktivierung. In neonatalen 
ventrikulären Rattenkardiomyozyten (NRVCM) lassen sich die durch Überexpression und 
Herunterregulierung gewonnenen Ergebnisse reproduzieren. Anschließend untersuchten wir 
die phänotypischen und molekularen Effekte von SUMO2 in NRVCM. SUMO2 induziert eine 
Hypertrophie in NRVCM, welche sich auch in Anwesenheit von ΔCnA weiter steigern lässt. 
Die SUMO2-induzierte Hypertrophie ließ sich durch CnA-Inhibitoren (Ciclosporin, Tacrolimus) 
aufheben. Eine Sumoylierungs-defiziente Mutante von SUMO2 (SUMO2ΔGG) hat 
überraschender Weise einen nahezu identischen Effekt wie das sumoylierungs-fähige SUMO2 
in allen untersuchten Parametern, was auf einen Mechanismus hindeutet, der unabhängig von 
einer kovalenten Modifikation mit SUMO2 ist. Ebenfalls konnten wir zeigen, dass nach 
Überexpression von ΔCnA zusammen mit SUMO2 oder SUMO2ΔGG, Calcineurin stärker im 
Zellkern lokalisiert ist, während dies bei einer reinen ΔCnA Überexpression nicht zu 
beobachten ist. 
Schlussfolgernd wurde SUMO2 als neuer und positiver Modulator des Calcineurin-NFAT 
Signalwegs identifiziert. Interessanter Weise sind diese Effekte Sumoylierungs-unabhängig 
und könnten auf eine nukleäre Retention von aktiviertem Calcineurin hindeuten.  
 
   
Introduction 
 
 
   11  
  
 
4 Introduction 
4.1 Overview 
For each disease a variety of signaling pathways, either alone or in concert, influence the fate 
of single cells and tissue on multiple levels leading to the disease-specific phenotype. External 
and internal stimuli direct the cell towards one or the other direction and are yet oftentimes 
poorly characterized. The deciphering of the crosstalk between different signaling pathways 
and stimuli causing a certain disease is of great importance to get a chance at delaying, 
stopping or ideally reversing a certain pathologic development. In this thesis, the calcineurin-
NFAT (nuclear factor of activated T-cells) signaling in the context of cardiomyocyte 
hypertrophy is the focus of investigation. Not only the individual transcription factors and 
therein directly involved proteins like phosphatases and kinases play a role in development of 
a disease. Important for the understanding of a certain mechanism or mechanistic feature is 
the investigation of posttranslational modifiers and protein-protein interactions that can cause 
a modulation of the signaling pathways. More so, this regulation can vary between different 
conditions within the cell and modulate according to an external or internal stimulus. Here, the 
mechanistic link between the calcineurin-NFAT axis and the system of small ubiquitin like 
modifier 2 is investigated on several levels of regulation. 
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4.2 Cardiac hypertrophy 
The heart’s reaction to elevated and enduring biomechanical stress is the development of 
cardiac hypertrophy. The term hypertrophy describes a distinct set of pathological events that 
can be observed in the cells involved. In terms of a hypertrophic heart, it firstly refers to an 
increased mass. This however is prone to bias due to the assumption that the increased mass 
results from increased cardiomyocyte size. Hearts that retained fluid or perfused hearts will 
have a different wet mass than otherwise harvested organs so the desiccated mass is a more 
reliable parameter apart from single-cell size comparison. A broad overview of cardiac 
hypertrophy and its cellular and organ consequences was given by Gerald W. Dorn in 2003 
(Dorn et al., 2003). 
Initially, this stress-response is physiologic, similar to the changes the heart undergoes when 
constantly challenged with exercise. This can be well observed in athletes for example. In this 
adaptive hypertrophy, the cardiac muscle cells grow to increase the function, meaning 
increased pressure and blood volume ejection overall and especially of the left ventricle. This 
compensation for the need of a stronger and more capable heart is beneficial. On the contrary, 
enduring pressure overload and thus biomechanical stress switches this adaptively 
compensating state to a maladaptive stage, where the mechanical capacity of the heart 
decreases. This is a harmful state for the heart and has to be treated accordingly. Often times 
this maladaptive state is a result of heart tissue remodeling followed by myocardial infarction, 
chronic hypertension or valvular heart disease, among others (Ertl and Frantz, 2005; Frantz et 
al., 2009; Pfeffer and Braunwald, 1990; Zwadlo and Borlak, 2005). Adaptive and maladaptive 
hypertrophy need to be well differentiated to be able to successfully modulate the disease 
outcome. To study the mechanistic features of cardiac hypertrophy, cell culture systems are 
needed to observe the adverse effects that various proteins and signaling molecules have on 
the disease outcome prior to the investigation in animal models and ultimately in humans. 
In cell culture the term hypertrophy also mainly refers to an increase in cell size, measured by 
the cell surface area but there are distinct genetic parameters adding to hypertrophy that can 
be precisely assessed. This increase in cell surface area is typically accompanied by the 
elevated expression of hypertrophy associated fetal genes, encoding for natriuretic peptides: 
nppa (protein: atrial natriuretic peptide) and nppb (protein: brain natriuretic peptide). Several 
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other genetic factors and protein expression patterns can be investigated but seem to vary 
according to the type of induction of hypertrophy such as pharmacologic stimulation or the 
generation of biomechanic stress through dynamic stretch of the individual cells. An 
involvement of calcineurin A in the hypertrophic response is often times accompanied by the 
increased expression of the regulator of calcineurin 1.4 (Rcan1-4) on both, RNA and protein 
levels as will be discussed in detail.  
All these factors taken together provide valuable information about the type of hypertrophy 
observed and can already provide hints on the involved proteins and signaling pathways. As 
an investigative means for the assessment of hypertrophic effects, hypertrophy can be 
pharmacologically induced within defined parameters in cell culture systems through the 
addition of the pharmacologic agent phenylephrine (PE). PE leads to an increased cell size 
and upregulation of the above described hypertrophy-associated fetal genes. This induction of 
cardiomyocyte hypertrophy typically occurs within 48 hours after stimulation. PE is a selective 
α1-adrenergic receptor agonist of the phenethylamine class and thus a sympathomimetic. 
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4.3 Calcineurin 
The protein calcineurin or PPP3CA (also known as PP2B) is a serine/threonine protein 
phosphatase that belongs to the PPP family of protein phosphatases. This family alone is 
responsible the main phosphatase activity of serine/threonine phosphatases in vivo. The family 
shows a conserved catalytic domain stretch of about 280 residues alongside non-conserved 
N- and C-termini. Their assembly varies and includes many different accessory proteins and 
distinct regulatory subunits (Barford et al., 1998). Originally isolated in 1976, calcineurin has 
been extensively studied over the last decades and throughout the different fields of research 
(Wang and Desai, 1976). Calcineurin is a heterodimer built up of two different subunits. The 
regulatory subunit calcineurin B (CnB) has a molecular weight of ~17 kDa and is smaller than 
the catalytic subunit calcineurin A (CnA). CnA has a molecular weight of approximately 59 kDa 
(Guerini et al., 1992). In mammals, there are three genes that encode for calcineurin A (α, β, 
µ), of which CnAα and CnAβ are expressed in the heart (Bueno et al., 2002b; Taigen et al., 
2000). The smaller regulatory subunit CnB is encoded by two genes, CnB1 and CnB2 of which 
only CnB1 is expressed in the mammalian heart (Ueki et al., 1992). The catalytic subunit of 
CnA is localized at the N-terminus, whereas the autoinhibitory domain (AID) is localized at the 
C-terminus as can be seen in Figure 1. The AID inhibits the catalytic domain, maintaining an 
inactive status of the protein. Upon binding of calcium/calmodulin on the one hand, or a 
cleavage of the AID by calpain, a calcium dependent protease on the other hand, the protein 
shifts to its active state (Bueno et al., 2002a; Burkard et al., 2005). The calcium/calmodulin 
binding domains are located c-terminal of the catalytic domain (Figure 1). Of note, elevated 
levels of activated calcineurin have been observed in the human hypertrophied and failing 
heart (Haq et al., 2001; Lim and Molkentin, 1999; Ritter et al., 2002). 
1
Calcineurin A
521
Autoinhibitory
domain
465 487171
NLS
190
Catalytic phosphatase  domains
NES
Calpain cleavage site
423
422
433
CnB binding
296-301247-253
 
Figure 1: Schematic drawing of calcineurin A with depicted domains, nuclear import and export sites as 
well as calpain cleavage site and autoinhibitory domain. 
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Many efforts have been taken to identify the role of calcineurin within the cell. A rise of 
intracellular Ca2+ levels activates calcineurin by conformational change and a displacement 
of its AID. Upon activation, calcineurin can dephosphorylate conserved N-terminal serine 
residues on cytoplasmic localized transcription factors such as members of the NFAT family, 
shifting their localization towards the nuclear compartment. In the nucleus, the NFAT 
transcription factors bind to the DNA as homodimer, heterodimer or monomer (Hogan et al., 
2003). Together with accessory proteins and other transcription factors like MEF2 or GATA1, 
and GATA4, NFATs can activate a set of pro-hypertrophic genes (Hogan et al., 2003; Wilkins 
et al., 2004; Wilkins and Molkentin, 2004). 
Calcineurin also has reported functions throughout the cell including contraction, metabolism, 
synaptic transmission, RNA splicing and cell cycle control (Beullens et al., 1992; Cohen, 1989; 
Shenolikar and Nairn, 1991; Wera and Hemmings, 1995). On the level of cell cycle regulation, 
it interacts with and inhibits the cyclin-dependent kinase CDC25, playing an inhibitory role in 
mitosis. CDC25 removes phosphates from various cyclin dependent kinases and subsequently 
activates them for cell-cycle progression (Wera and Hemmings, 1995). There are a variety of 
other examples where calcineurin has influence on cell cycle progression and other signaling 
pathways, reviewed in a variety of articles from different fields of research.  
4.3.1 Animal models for calcineurin-NFAT signaling 
The importance of calcineurin regarding signal-transduction in the heart and specifically the 
involvement in the pro-hypertrophic signaling pathways gave rise to a variety of different animal 
models in which the protein phosphatase was further characterized and validated for 
physiologic and pathophysiologic relevance. 
Activation of the Calcineurin-NFAT pathway in transgenic mice overexpressing a constitutively 
active mutant of Calcineurin causes a strong cardiac hypertrophy with severe fibrosis and 
activation of the molecular hypertrophic program (Molkentin et al., 1998). Moreover, 
cardiomyocytes from these mouse hearts are disorganized and hypertrophic, accompanied by 
a doubling of the cross-sectional area compared to wild type cardiomyocytes. The opposite 
effect can be achieved by inhibition of Calcineurin-NFAT signaling that can be observed in 
calcineurin Aβ−/− and Nfatc3−/− and Nfatc2−/− mice, leading to the inhibition of pathological 
cardiac hypertrophy in response to pressure overload or stimulation with neuroendocrine 
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agonist infusion (Bueno et al., 2002b; Molkentin et al., 1998; Wilkins et al., 2002). Both findings 
demonstrate a critical and indispensable role Calcineurin-NFAT signaling plays in the 
pathological remodeling of the heart and their sufficient and necessary role in the development 
of cardiac hypertrophy following biomechanical stress. 
4.3.2 Subcellular localization 
It has been reported, that depending on the availability of calmodulin, different concentrations 
are needed for an activation of calcineurin (Stemmer and Klee, 1994). With higher 
concentrations of calmodulin within the cell, less Ca2+ is needed for a full activation of 
calcineurin. For a complete activation however, Ca2+ levels similar to those present in the cell 
during the systole are needed. Calcineurin might therefore integrate the contractile Ca2+ signal 
and decode alterations of its frequency into subcellular signaling and even that of rapid Ca2+-
oscillations (Colella et al., 2008). Concluding from this, a separation between “contractile” and 
“signaling” Ca2+has been proposed (Molkentin, 2006). The signaling-calcium is thought to be 
active in specific micro domains within the cell that are insulated from the fluctuating contractile 
calcium. In those micro domains, proteins are exposed to high local amounts of Ca2+ alongside 
their target molecules, which could also explain why the high concentrations of calcineurin 
present in the cytosol (Heineke et al., 2010) are not undergoing constant activation, due to the 
high levels of Ca2+ during the muscle contraction. The cytoplasmic calcineurin might thus be 
located in micro domains for example together with the different NFAT target proteins and 
becomes activated only upon calcium/calmodulin binding or calpain cleavage (Heineke and 
Ritter, 2012). A complete inhibition of calcineurin in failing or hypertrophied hearts seems to 
be a possible therapeutic means, however this leads to severe heart failure and accelerated 
death in mice (Maillet et al., 2010). There, the ablation of the regulatory calcineurin subunit 
CnB1 completely abrogates CnA protein in the heart. For this reason, instead of an unspecific 
complete inhibition, Heineke and Ritter propose a micro domain-specific inhibition for a 
possible therapeutic approach (Heineke and Ritter, 2012). The classical role for calcineurin as 
a cytoplasmically localized protein phosphatase that mediates signaling effects by mere 
activation of NFAT through dephosphorylation of the transcription factor has been challenged 
early on by various research groups. Interestingly, it has been shown that a subpool of 
calcineurin itself also translocates to the nucleus (Burkard et al., 2005), implying the existence 
 
   
Introduction 
 
 
   17  
  
 
of additional targets for dephosphorylation or even a distinct interacting role for calcineurin with 
the transcription factor apart from a dephosphorylation. 
In failing human hearts, a significant increase in nuclear calcineurin levels has been reported 
(Burkard et al., 2005), hinting at an important role for calcineurin in the development or 
maintenance of cardiac disease, mediated by this nuclear subpool. When calcineurin’s AID is 
targeted and cleaved by the protease calpain, it becomes constantly active and independent 
of calmodulin but not Calcium as well as it translocates to the nuclear compartment (Stemmer 
and Klee, 1994; Yang and Klee, 2000). The cleavage exposes the phosphatase domain and 
thus enhances the enzyme activity. Interestingly, the nuclear localization sequence (NLS) is 
also exposed upon cleavage and at the same time, the nuclear export sequence (NES) is 
removed alongside the AID (Heineke and Ritter, 2012). Calcineurin can be exported from the 
nucleus by the export-protein Crm1 or exportin. Once devoid of its NES, Crm1-mediated 
shuttling cannot occur and constitutively active calcineurin is retained in the nuclear 
compartment (Hallhuber et al., 2006). This is particularly interesting since the constitutively 
active calcineurin is now shuttled into the nucleus and because of the lack of the NES, will be 
retained there, even after the loss of a pro-hypertrophic stimulus (Hallhuber et al., 2006). The 
method of calcineurin import through the nuclear pore complex (NPS) is Ran-GTP mediated 
and energy dependent (Gorlich et al., 2003; Hallhuber et al., 2006; Jans et al., 2000; Rout and 
Aitchison, 2001). The precise role of active CnA in the nucleus remains elusive. For one, the 
classical phosphatase role for the activation of NFAT in the nucleus can be executed similar 
to the originally identified NFAT-dephosphorylation occurring in the cytoplasm. A nuclear 
subpool of calcineurin could also counteract the role of different kinases present in the nucleus 
to shift the reaction-equilibrium towards the side of dephosphorylated and consequently active 
DNA-bound NFAT. Examples of nuclear localized kinases are glycogen synthase kinase 3 
beta (GSK3β) and c-Jun N-terminal kinase (JNK) as well as the dual-specificity tyrosine 
phosphorylation-regulated kinase 1A (DYRK1A) (Antos et al., 2002; Chow et al., 1997; Kuhn 
et al., 2009). However, experiments showed that phosphatase-deficient, mutated calcineurin 
constructs can also block the NFAT-export, suggesting that counteraction of kinase activity is 
not a major mechanism of action mediated by nuclear calcineurin (Zhu and McKeon, 1999). 
Lastly, NFAT-bound calcineurin seems to inhibit the Crm1-mediated export of NFAT from the 
nucleus to the cytoplasm by masking NFAT’s NES (Zhu and McKeon, 1999). Nuclear 
calcineurin could therefore displace Crm1 from NFAT nuclear export sequence to retain 
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calcineurin-NFAT complexes in the nucleus with successive enhanced transcription factor 
activity (Hogan et al., 2003; Hogan and Rao, 1999; Zhu and McKeon, 1999). Heineke and 
Ritter conclude in their review, that truncated and constitutively active nuclear calcineurin 
mainly exhibits its functions by an interference with Crm1-mediated export of NFAT (Heineke 
and Ritter, 2012). 
4.3.3 Calcineurin inhibitors 
The research efforts taken for the identification of endogenous modulators of calcineurin 
activity have been large, their majority yielding the identification of proteins that have an 
inhibitory effect on the phosphatase activity. A variety of CnA inhibitors have been published 
so far. For example the protein Cain is an inhibitor for calcineurin in neurons that acts in a non-
competitive way (Lai et al., 1998). The protein AKAP79 however directly interacts and blocks 
calcineurin activity in cardiomyocytes and acts as a competitive inhibitor (Taigen et al., 2000). 
Another example for inhibition of CnA by other proteins is a protein family called calsarcins. 
These proteins are necessary for the induction of a hypertrophic calcineurin-NFAT response 
by a negative regulation of CnA phosphatase activity and consequently NFAT activation (Frey 
et al., 2000). Along the same lines, the animal model of calsarcin-1 knockout mice show 
exaggerated hypertrophy following pressure overload (Frey et al., 2008). Apart from interacting 
and thereby inhibiting proteins, there are two pharmacologic agents known to inhibit CnA, 
ciclosporin A (CsA) and FK506/tacrolimus. These two substances have been widely used in 
immunosuppressant therapy following organ transplant action. Interestingly the mechanism of 
action has been unclear as they were only later found to inhibit calcineurin not directly, but by 
binding to endogenous immunophilin proteins, cyclophilin A and FKBP12, respectively (Liu et 
al., 1991). Liu and colleagues utilize purified CnA from bovine brain tissue and described a 
retention effect of calcineurin, when FK506-FKBP12 or CsA-cyclophilin A complexes bind to 
calcineurin and also calcineurin-calmodulin complexes subsequently rendering the 
phosphatase inactive (Liu et al., 1991). This is another example of how calcineurin influences 
signal transduction in other cell-types apart from muscle-tissue. Another important modulator 
of the Calcineurin-NFAT signaling pathway is Rcan1-4. Changes in the Rcan1-4 protein levels 
can be assessed to endogenously indicate the activation of calcineurin-NFAT signaling (Yang 
et al., 2000). The expression of Rcan1-4 is regulated by NFAT transcription factors, yet its 
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precise function is still under debate. This is due to both inhibitory and activator roles that have 
been observed by different groups and under various experimental conditions (Fox and 
Heitman, 2005; Sanna et al., 2006; Vega et al., 2003a; Vega et al., 2003b). A more recent 
study however suggests a diverse role for Rcan1-4, using a systems biology approach and 
single-cell experimentation in combination with in silico simulations. In this study, Shin and 
colleagues suggested a dose dependent effect of Rcan1-4 as an inhibitor at lower levels but 
as a facilitator at higher expression levels, which highlights the complexity of calcineurin 
regulation (Shin et al., 2011). On the activator-side of calcineurin interacting proteins, a protein 
termed Dyxin/LMCD1 has been reported that may act as a strong activator of calcineurin-
mediated cardiac hypertrophy (Frank et al., 2010). 
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4.4 Small ubiquitin-related modifiers – SUMO proteins 
4.4.1 Overview 
SUMO (small ubiquitin-related modifier) proteins were originally identified as post-translational 
modifiers. Two initial studies link SUMO1 to binding with RAD51 and RAD52 (Chen et al., 
1998; Shen et al., 1996) and finally SUMO1 was found to covalently bind to RanGAP1 (Matunis 
et al., 1996). This initial finding of a covalently attached SUMO already hinted at the influence 
that SUMO1 has on subcellular-localization because it was found that unsumoylated 
RanGAP1 remained cytoplasmically localized, whereas sumoylated RanGAP1 translocated to 
the nucleus that implies a fundamental regulating role for SUMO1 in the nuclear-cytoplasmic 
trafficking of various proteins. The reversibility of this process was yet another groundbreaking 
finding from the original study and opened the door for a variety of characterization approaches 
as well as the generation of hypothesis for SUMO’s mechanisms of action. Apart from the 
already discovered ubiquitin protein, with SUMO1 these studies laid the foundation for the 
investigation of yet another family of posttranslational modifiers and their role in cell-signaling 
and disease development. The discovery of the reversibility of sumoylation rapidly led to the 
characterization of the responsible proteases and ever since an increasing amount of SUMO-
interacting proteins were discovered, their majority being localized in the nucleus. With the 
characterization of SUMO, a consensus-sequence for sumoylation evolved that proved a 
useful tool for the studies of sumoylation-dependent processes. As a method for the 
observation of SUMO-mediated effects, potential SUMO-binding sites could now be artificially 
mutated and sumoylation competent- and incompetent proteins were compared. Apart from 
sumoylation, SUMO-proteins can modify proteins by non-covalent interaction through so-
called SUMO-interaction/binding-motifs (SIM/ SBM), adding another layer of complexity to this 
type of post-translational modification. 
The family of SUMOs comprises four distinct and structurally similar proteins (SUMO-1, -2, -3 
and -4) whose functions were reviewed in great detail by Melchior and Geiss-Friedlander 
(Geiss-Friedlander and Melchior, 2007). All of the SUMOs are 10-15 kDa in size, sharing many 
secondary-structural elements with the name-giving protein ubiquitin B (Figure 2). All shown 
proteins share a common set of tertiary structure elements with two alpha-helices and four to 
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five beta-sheets. Amino-acid similarity between SUMO proteins and ubiquitin however does 
not exceed 20%. The overall surface charge of SUMOs and ubiquitin differs as well. SUMO 
proteins are expressed as precursor molecules containing a C-Terminal diglycine-motif (X-Gly-
Gly-X) followed by a varying amount of different amino-acids. The diglycine motif has to be 
exposed by C-terminal cleavage in order for SUMOs ability to be covalently attached to target 
proteins as further described in 4.4.3. The expression of SUMO1-3 is ubiquitous throughout 
the organ system and various cell types of many species whereas SUMO4 seems to be majorly 
expressed in the kidney, spleen and lymph node (Guo et al., 2004). The primary structures of 
processed SUMO2 and SUMO3 are 97% identical and the proteins are commonly referred to 
as SUMO2/3 due to a lack of knowledge about individually delimiting functions. Both share 
only about 50% sequence similarity with SUMO1 which results in distinct conjugation to 
different target proteins in vivo (Saitoh and Hinchey, 2000). 
Ubiquitin B
PDB: 1AAR
SUMO1
PDB: 4WJQ
SUMO2
PDB: 1WM2
SUMO3
PDB: 1U4A
 
Figure 2: Side-by-side comparison of human ubiquitin B, SUMO-1, -2 and -3 with alpha-helices shown 
in pink and beta-strands shown in yellow. All structures were extracted from the RSCB Protein database 
(Cappadocia et al., 2015; Cook et al., 1992; Ding et al., 2005; Huang et al., 2004). 
4.4.2 The SUMO family 
Human SUMO1 was originally discovered in yeast as SMT3 and was cloned to identify 
suppressors of the temperature-sensitive MIF2 allele. SUMO1 contains the characteristic 
ubiquitin-fold ββαββαβ that is preserved among ubiquitin-like proteins as reviewed by Mayer 
and colleagues (Mayer et al., 1998). Ubiquitin and SUMO1 share 50% of their amino acid 
sequence and the secondary and tertiary structure are closely related as can be seen in Figure 
2. Even though both proteins are structurally close, the proteins involved in the processing and 
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subsequent ligation are related, but not identical. While ubiquitin is typically attached to target 
proteins in poly-ubiquitin chains and therefor often attached to itself (Pickart, 1997), SUMO1 
does not seem to be able to self-conjugate when covalently attached, supposedly because the 
lysine residues used for poly-ubiquitination are not conserved within SUMO1.  
The investigation of the effect that a SUMO1-knockout had on mice, lead to somewhat 
contradicting studies. Alkuraya and colleagues studied a patient with cleft lip and palate caused 
by a chromosomal translocation with disrupted SUMO1 gene. In the SUMO1-knockout mouse 
model they could recreate the cleft lip phenotype and also observed embryonic demise 
between E13.5 and E18.5 and immediate postnatal death (Alkuraya et al., 2006). Contradicting 
with this finding is a study of SUMO1-knockout mice in which the last three SUMO1-exons 
were targeted for disruption (Zhang et al., 2008). SUMO-1 mRNA abundance was halved in 
heterozygotes and undetectable in Sumo-1(-/-) mice. Further, SUMO-1-conjugated RanGAP1 
was undetectable in SUMO1-knockout mice. The authors neither observed embryonic or early 
postnatal lethality nor a defect in lip and palate development in knockout mice. They concluded 
that that most, if not all, SUMO-1 functions are compensated for, in vivo, by SUMO-2 and 
SUMO-3. 
The SUMO conjugation plays a critical role in embryogenesis. Mouse embryos that are 
deficient in the SUMO-E2 enzyme UBC9 die at the post implantation stage (Nacerddine et al., 
2005). Yuan and colleagues show an indispensable but functionally redundant role for SUMO-
paralogues for the early zebrafish development (Yuan et al., 2010). Driven by these studies, 
Wang and colleagues studied the effect of SUMO2 and SUMO3 in mouse with knockdown 
approaches for both proteins (Wang et al., 2014). They show viable SUMO3-knockout mice 
whereas SUMO2-knockout mouse embryos exhibited severe developmental delay and died at 
embryonic day 10.5. Including additional evidence for SUMO2 being the predominantly 
expressed isoform. Furthermore they could show that SUMO2 and SUMO2/3 heterozygous 
mice lacked any overt phenotype, concluding that the expression levels but not functional 
differences between SUMO2 and SUMO3 are critical for normal embryogenesis. 
Apart from the finding that SUMO4 seems to be majorly expressed in the kidney, spleen and 
lymph node, not much is known about its functions to date (Guo et al., 2004). SUMO4 shares 
90% nucleotide identity and 87% amino acid homology with SUMO2. Patients with a single 
nucleotide substitution and subsequently altered amino-acid Methionin55 to Valine show a 
strong association to type 1 diabetes, however no mechanistic link is provided yet apart from 
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a suggested interaction with IκB and subsequently enhanced NFκB activation (Guo et al., 
2004; Hwang et al., 2011). SUMO4 has so far not been investigated in animal-models. 
4.4.3 Posttranslational modification: sumoylation 
The majority of the discovered SUMO-involved mechanism is mediated by its ability to be 
covalently attached to target proteins. As can be seen in Figure 3, many proteins are involved 
in the sumoylation process. Firstly, the expressed precursor SUMO-protein with a variable 
stretch of amino acids following the diglycine motif has to be cleaved off by so called sentrin-
specific proteases (SENP). The cleaved SUMO has to be activated in an ATP-dependent 
reaction involving a protein complex called the E1-activating enzyme heterodimer comprised 
of UBA2 and AOS1 (Lin et al., 2003; Xu and Au, 2005) which attaches the adenylate-SUMO 
conjugate intermediate to UBA2. In the next step, SUMO is transferred from the E1-complex 
to the E2-conjugating enzyme UBC9, linking the catalytic cysteine residue to the C-terminal 
carboxy-group of SUMO (Saitoh et al., 1998; Ueki et al., 1992). Of note, the E2-conjugating 
enzyme UBC9 is only an E2-enzyme for SUMO-proteins but not for ubiquitin (Stemmer and 
Klee, 1994). In a last step, SUMO is transferred to its target protein, forming an isopeptide 
bond between the target lysine and the C-terminal carboxy-group of SUMO’s glycine residue. 
This process is typically catalyzed by E3-ligase enzymes, which contain a SP-RING motif, 
similar to the ubiquitin RING E3-ligases (RE) which are essential for the enzyme’s function 
(Hochstrasser, 2001). SP-RING ligases bind their targets directly and bind to SUMO in a non-
covalent way through SUMO-interacting motifs, thus possibly functioning as scaffolding 
proteins to bring the relevant residues in close proximity and consequently catalyzing the 
isopeptide-bond formation.  
Even though the majority of sumoylation processes result in a single SUMO attachment to a 
target lysine, mammals possess the ability to form poly SUMO chains, very similar to poly 
ubiquitin chains which could be shown for SUMO2/3 in mammals (Mukhopadhyay et al., 2006; 
Tatham et al., 2001). In addition to their initial cleavage of the SUMO precursor proteins, the 
sentrin specific proteases can also reverse the process of sumoylation by their isopeptide 
cleavage activity (Di Bacco and Gill, 2006; Di Bacco et al., 2006; Gong and Yeh, 2006). The 
challenging and fascinating circumstance is, that there is no easy way to determine, which 
result a SUMO-conjugation or interaction will have on a given target protein yet. 
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Figure 3: Schematic overview of the sumoylation enzyme-cascade. Figure, modified from (Geiss-
Friedlander and Melchior, 2007), page 498. 
4.4.4 Consequences of sumoylation and SUMO-interaction 
The molecular consequences of sumoylation of a given target protein or the SUMO-interaction 
are difficult to assess and very diverse. Sumoylation can enable or enhance protein-protein 
interactions on the one hand, but on the other hand can also disturb those interactions. For 
example RanGAP1 interacts with RanBP2 upon sumoylation (Brattstrom et al., 2010; Matunis 
et al., 1996) whereas sumoylated E2-25K loses its interaction capability with the ubiquitin E1-
enzyme (Pichler et al., 2005). Another example is a study, where the mutation of the SUMO 
acceptor site in CtBP1, K428R, shuttles CtBP1 from the nuclear compartment to the cytoplasm 
(Lin et al., 2003). 
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One possible molecular consequence of sumoylation is the modulation of DNA binding-abilities 
of transcription factors. An example is the hepatoma-derived growth factor (HDGF) that loses 
its DNA binding affinity in comparison to the non-sumoylated protein (Goodson et al., 2001). 
In contrast to this, the sumoylation of the heat shock transcription factor 2 (HSF2), that plays 
a critical role in the modulation of heat shock protein expression upon external stimulation, 
enhances its DNA-binding affinity (Thakar et al., 2008). This is a good example for the diversity 
of SUMO-interaction consequences and that the same modification can have on two different 
transcription factors. 
The alteration of protein-protein interaction can also be a result of sumoylation. Sumoylated 
aryl hydrocarbon receptor repressor (AhRR) will partially enhance its inhibitory effect on the 
receptor activity as a result of a potentiated interaction of sumoylated AhRR with its 
corepressors (Oshima et al., 2009).  
The increase of protein turnover and degradation has for a long time only been linked to 
ubiquitination and not sumoylation. This has been challenged in 2007, when Prudden and 
colleagues could show in yeast, that SUMO specific ubiquitination E3-ligases targeted 
sumoylated proteins for degradation (Prudden et al., 2007). Since then, many other proteins 
have been implicated with enhanced degradation upon sumoylation, broadening the range of 
molecular consequences of sumoylation and SUMO-interaction. 
SUMO interaction and sumoylation can thus be regarded, as extenders of possible protein-
protein interactions and their modulation capabilities are promising targets to link basic 
molecular interaction studies to possible disease development and/or progression. 
4.4.5 SUMO interaction / binding motif (SIM/SBM) 
Apart from the well-studied sumoylation modifications, there has been a rather recent 
discovery of non-covalent sumo-interaction or –binding motifs (SIM/SBM) (Hecker et al., 2006; 
Song et al., 2004) which influence their targets, all of which are themselves sumoylated 
proteins (Lin et al., 2006; Minty et al., 2000; Shen et al., 2006; Song et al., 2004). The 
understanding of SUMO protein function and mechanistic biology has been majorly advanced 
with the knowledge about SUMO interaction. Unlike the motifs that mediate ubiquitin binding, 
SUMO binding motif diversity seems more limited and is not fully understood and characterized 
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(Kerscher, 2007). First in 2000, Minty and colleagues identified a specific SUMO interacting 
protein with conserved SIM/SBM sites (Minty et al., 2000). In a yeast-two-hybrid system they 
could show an interaction with the sumoylated version of the protein p73. By sequence 
comparison, they revealed a common Serine-X-Serine (S= serine, X=hydrophobic amino acid) 
motif. They proposed that the two serine residues flanking the hydrophobic (-X-) core are 
required for SUMO interaction. This motif however was challenged four years later by Song 
and colleagues who proposed a different consensus sequence, also from yeast-two-hybrid 
experiments (Song et al., 2004). They suggested a motif with a hydrophobic core and a 
consensus sequence of V/I-X-V/I-V/I (V= valine, I= isoleucine) that can be found in many 
proteins, including those already identified as sumoylation targets. The structure of the 
SUMO1-PIASX complex reveals the interaction to lie between individual hydrophobic and 
aromatic residues between SUMO and the interacting peptide (Song et al., 2005). For SUMO1 
and SUMO2 it could be shown, that this interaction assumedly lies within the groove between 
the α-helix one and the β-strand two. From NMR and crystal structures, crucial hydrophobic 
residues of SUMO1, e.g. valines, phenylalanines and Leucines have been found to interact 
with SIM on target proteins (Baba et al., 2005; Hecker et al., 2006). One example is that 
SUMO1 can inhibit RAD51-mediated homologous recombination by interaction with RAD51 
(Li et al., 2000). Along the same lines and also through SUMO interaction, SUMO1 can protect 
against cell decay by interacting with Fas and tumor necrosis factor receptor 1 (TNFR1) (Okura 
et al., 1996). The inhibition of dynamin-dependent endocytosis was also shown to be mediated 
through sumoylation-independent SUMO1 binding (Mishra et al., 2004). As an example for 
another SUMO-protein, SUMO3 was found to co-activate EBNA2 (Epstein-Barr virus nuclear 
antigen 2) in the absence of direct conjugation to EBNA2 (Rosendorff et al., 2004). These are 
just a few of the many examples of already known SUMO interactions with various proteins 
and the investigation of the interactions as well as the characterization of new tentative 
SIM/SBM will provide valuable information about the SUMO-family mediated modulation of 
proteins and signaling pathways. 
4.4.6 Implications in cardiac disease 
SUMO can modulate a variety of proteins that are important for gene regulation, including 
various transcription factors involved in fetal gene expression and heart development as well 
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as pro-hypertrophic signaling pathways, cell cycle regulation, transcription and subcellular 
transport (Kim and Baek, 2009) via alterations in molecular interaction patterns of the modified 
target (reviewed in (Geiss-Friedlander and Melchior, 2007)). Examples for SUMO-modified 
transcription factors that are involved in normal cardiac development are Nkx2.5 (Wang et al., 
2008), GATA binding protein 4 (GATA4) (Komatsu et al., 2004; Wang et al., 2004), the serum 
response factor (SRF) (Matsuzaki et al., 2003) and myocardin (Wang et al., 2007). The 
involvement of SUMO in such a variety of transcription factors involved in cardiac development 
supports an important role for SUMO-modification in the heart. SUMO2 among other SUMO 
family members has recently been implicated in cardiac disease as extensively reviewed by 
Wang and Schwartz (Maejima and Sadoshima, 2014; Wang, 2011; Wang and Schwartz, 
2010). Therefore, studying the effect of SUMO2 in this context is potentially very valuable. A 
particularly promising example of SUMO implication in cardiac disease in human was 
investigated by Kho and others, who discover a link between SUMO1 and the regulation of 
SERCA2a in the context of heart failure, stabilizing the protein and its ATPase activity (Kho et 
al., 2011). In failing hearts, sumoylation of SERCA2a and overall levels of SUMO1 were 
reduced (Kho et al., 2011). Also they could rescue the contractile function mice with induced 
hypertrophy by SUMO1 gene transfer. Last year, Gupta and others showed that the SUMO-
conjugating enzyme UBC9, which is the only known SUMO2-E2 enzyme yet, is of importance 
for protein maintenance in cardiomyocytes (Gupta et al., 2014). They used loss- and gain of 
function approaches to study the importance of the SUMO E2-enzyme UBC9. They found out 
that an overexpression of UBC9 elevated the function of the ubiquitin proteasome system 
(UPS) in cardiomyocytes, whereas knockdown of UBC9 by small interfering RNA (siRNA) 
caused significant accumulations of aggregated protein (Gupta et al., 2014). A particularly 
interesting finding for this study is the implication of SUMO2 in human cardiomyopathy in a 
way where reduced sumoylation of the protein Lamin A resulted in enhanced cell death. Lamin 
A is a direct SUMO2 target with two known naturally occurring mutants that are directly 
associated to familial cardiomyopathy. Those natural mutations are localized in a sumoylation 
consensus-motif around Lysine201 (Zhang and Sarge, 2008).  
Another interesting implication for SUMO-proteins in cardiac disease is an overexpression 
approach of the sentrin-specific protease 5 (SENP5) that is responsible for the reversible 
sumoylation by cleaving SUMO-proteins off their targets. Kim and colleagues show that the 
levels of SENP5 are significantly increased in human idiopathic failing hearts (Kim et al., 2015). 
 
   
Introduction 
 
 
   28  
  
 
Cardiomyocyte-specific overexpression of SENP5 led to cardiac dysfunction, accompanied by 
decreased cardiomyocyte proliferation and elevated apoptosis. SUMO attachment to dynamin 
related protein (Drp1), a factor critical for mitochondrial fission was decreased. The authors 
suggest the SUMO conjugation pathway as a potential target in the prevention/treatment of 
cardiomyopathy.  
4.5 Rationale 
The role for the calcineurin-NFAT signaling axis has been under investigation for a long time, 
yet mainly inhibiting molecules were discovered for this significant pathway that plays a pivotal 
role in the development of cardiac hypertrophy and other cardiac diseases. For a possible 
therapeutic use, activators of this pathway needed to be identified in order to a) understand 
the mechanism of action that activates calcineurin for pathologic signaling and b) study the 
chances for a successful indirect inhibition of this pathway by regulation of calcineurin 
activators. The purpose of this study was to identify yet unknown activating modulators of 
calcineurin-NFAT signaling in the heart. Therefor a screening approach was utilized where an 
NFAT-reporter driven luciferase construct was stably transfected into mouse myoblasts. These 
cells were then exploited by co-transfection with calcineurin and an unknown pool of cDNAs 
to reveal those coding sequences that activate calcineurin signaling by observing the 
subsequent NFAT activation in the different conditions. This approach revealed the small 
ubiquitin related modifier 2 (SUMO2) to be a strong activator of calcineurin-NFAT signaling. 
From the screening, a series of tasks for this thesis evolved that include I) the thorough 
characterization of the structural and functional interaction between SUMO2 and calcineurin 
II) the investigation of the effect of gain- and loss of function approaches III) the observation of 
SUMO2’s influence on cardiomyocyte hypertrophy and ultimately IV) to encode the underlying 
mechanism of action by which SUMO2 mediates its effects on the cell. 
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5 Material and methods 
5.1 Materials 
5.1.1 Hardware and consumables 
Amersham Hybond-P PVDF membrane GE Healthcare 
Axiovert 40 C Microscope   Zeiss 
Cell Scraper 16cm 2-position blade  Sarstedt 
Cellstar cell culture dishes 6-, 12-,  
24-well, 6cm-, 10cm dishes   Greiner Bio one 
Centrifuge 5810    Eppendorf 
CFX96 Real-Time PCR Detection Sys BioRad 
Coverslips 18 mm diameter   Karl Hecht KG 
Duomax 1030 horizontal rotator  Heidolph 
DynaMag-2 Magnetic Particle Conc. Invitrogen  
ECX-F26.M UV-trans illuminator  Peqlab 
Electroporation cuvette   Peqlab 
Filter, paper 110 mm diameter  Schleicher & Schuell 
FluorChem Q Camera (Western Blot)  Alpha Innotech 
Galaxy Ministar Microcentrifuge  VWR 
Heraeus Fresco 21 Centrifuge  Thermo Scientific 
Heraeus Pico 21 Centrifuge   Thermo Scientific 
 
   
Material and methods 
 
 
   30  
  
 
Horizon 11-14 Gel-electrophoresis  Life Technologies 
Infinite M200Pro microplate reader  Tecan  
Mini PROTEAN Tetra System  Bio Rad 
Mr. Frosty™ Freezing Container  Thermo Scientific 
MyCycler Thermal Cycler   Bio Rad 
NanoDrop 2000 spectrophotometer  Thermo Scientific 
Neubauer- cell counter   Assistent 
Slide 76x26x1 mm    MARIENFELD 
Olympus BX53 microscope   Olympus 
Olympus DP72 camera   Olympus 
Parafilm     BEMIS 
Pasteur pipettes, glass   ROTH 
Pipettes Eppendorf-Reference  Eppendorf Research 
Pipette tips Biosphere Filter Tip  Sarstedt 
Pipette tips, with filter    Sarstedt 
Pipetus     Hirschmann Laborgeräte 
Power Pac HC    Bio Rad 
PP-Microplate 96-well   Greiner-Bio One 
RCT Basic magnetic stirrer   IKA 
Tubes 0.5 mL, 1.5 mL, 2 mL, 5 mL  Sarstedt 
Tubes 15 ml, 50 ml    Sarstedt 
Pipettes 2 mL, 5 mL, 10 mL, 25 mL  Sarstedt 
Precellys 24 homogenizer   Peqlab 
qRT-PCR plates, 96-well, semi skirted Bio-Rad 
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Seven Easy pH-meter   Mettler-Toledo 
Stemi 2000-C microscope   Zeiss 
Steril-Cult 200 incubator   Labotect 
Sterile filter 0.2µm pores   Nalgene Labware 
SterilGARD Hood     The Baker Company 
TE1502S precision scale   Sartorius 
Thermomixer Comfort   Eppendorf 
Titan PCR-working station    Scanlaf 
Vacusafe ventilation    Integra Biosciences 
Variomag Poly magnetic stirrer  Thermo Scientific 
Vortex-Genie 2    Scientific Industries 
Cell culture flasks 75cm2, 175cm2  Sarstedt 
5.1.2 Chemicals 
Agarose     Biozym Scientific GmbH 
Albumin fraction V, bovine   Merck KG 
Carbenicillin     Sigma-Aldrich 
DAPI      Sigma-Aldrich 
DEPC      Sigma-Aldrich 
DMEM      PAA Laboratories 
DMSO      Sigma-Aldrich 
DNA Loading Dye 6x    Fermentas 
Collagen I – solution, bovine skin  BD Biosciences 
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DreamTaq 10x green buffer   Thermo Scientific 
DynaBeads Protein G sepharose  Novex by Life Technologies 
EDTA      Serva Electrophoresis 
Ethanol     Carl Roth 
Ethidiumbromide    Invitrogen 
FCS Gold     PAA Laboratories 
Fluor Preserve Reagent    Calbiochem 
Formamide     Sigma-Aldrich 
GeneRuler 1kb Plus DNA Ladder  Fermentas 
HEPES     Carl Roth 
Hygromycin B     Invitrogen 
Ionomycin     Sigma-Aldrich 
iQ PowerMix Reagent, multiplex qRT Bio-Rad 
Kanamycine     Sigma-Aldrich 
Lipofectamine 2000 Reagent  Invitrogen 
Methanol     Carl Roth 
NCS (Newborn Calf Serum)   PAA Laboratories 
PageRuler Plus prestained Protein Ladder Thermo Scientific 
Penicillin/Streptomycin   Invitrogen/GIBCO 
Phenol/Chloroform/Isoamylalcohol  Carl Roth 
Phenylephrine    Sigma-Aldrich 
PMA (Phorbol-12-myristat-13-acetat) Sigma-Aldrich 
Protein-Assay dye-concentrate (Bradford) Bio-Rad 
QIAzol Lysis Reagent   Qiagen 
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Sodium chloride    AppliChem 
Sodium hydroxide    AppliChem 
SDS      Serva Electrophoresis 
Spectinomycin    Sigma-Aldrich 
TEMED 99% p.a. Electrophoresis  ROTH 
Tris-Base      Carl Roth 
Tris-HCl     Carl Roth 
Triton X 100     Serva Electrophoresis 
Trypane blue     Sigma-Aldrich 
Tween 20     Sigma-Aldrich 
Vectashield HardSet Mounting Medium Vecta-Labs   
5.1.3 Enzymes 
Collagenase type 2    Worthington/Cellsystems 
Complete-Proteinase Inhibitor Cocktail Roche Diagnostics 
Desoxyribonuclease I (DNase I)  Sigma-Aldrich 
DreamTaq DNA-Polymerase  (GreenTaq) Thermo Scientific 
LR-Clonase ™ II    Invitrogen 
Pac I      BD Biosciences Clontech 
BP-Clonase ™ II    Invitrogen 
Platinum® Pfx DNA Polymerase  Invitrogen 
Phosphatase-Inhibitor 2 und 3  Sigma-Aldrich 
Proteinase K     Invitrogen 
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Trypsin-EDTA-solution   Invitrogen/GIBCO 
5.1.4 Antibodies 
5.1.4.1 Primary Antibodies 
Table 1: List of primary antibodies, IF=Immunofluorescence, WB=Western Blot, IP= 
Immunoprecipitation. 
Antibody anti- species clonality Company Description 
Alpha-Actinin mouse Mono Sigma-Aldrich IF 
Calcineurin A mouse Mono Transd. Lab (BD) IF / WB 
Calcineurin A mouse Mono Sigma-Aldrich IP 
SUMO2/3 ab mouse mono Abcam IF / IP 
SUMO2/3 CS rabbit mono CellSignaling IF / WB 
α-Tubulin mouse mono Sigma WB 
Gapdh mouse mono Sigma WB 
β-Actin mouse mono Sigma WB 
SUMO1 rabbit poly CellSignaling WB 
Ubiquitinated Proteins mouse mono Millipore WB 
Rcan1-1&1-4 rabbit poly in-house WB 
Hexon-FITC coupled mouse mono Sigma-Aldrich WB 
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5.1.4.2 Secondary Antibodies 
Table 2: List of secondary antibodies, IF=Immunofluorescence, WB=Western Blot, HRP= Horseradish 
peroxidase, AF=AlexaFluor®. 
Antibody anti- species conjugate Company Description 
mouse goat HRP SantaCruz WB 
rabbit goat HRP SantaCruz WB 
mouse donkey AF546 Life Technologies IF 
mouse sheep FITC Life Technologies IF 
mouse goat AF488 Life Technologies IF 
mouse donkey AF546 Life Technologies IF 
rabbit donkey FITC Life Technologies IF 
rabbit goat AF488 Life Technologies IF 
 
5.1.5 Oligonucleotides and Primers 
Table 3: Oligonucleotide primers for the generation of open reading frame (ORF) fragments of the target 
gene. Primers are flanked by partial attB1 (forward) and attB2 (reverse) adapters to amplify with the 
attB1/2 adapter primers in a second PCR and to yield gateway® compatible fragments. 
Primer name Sequence 5' -> 3' Description 
attB_SUMO2-F TTCCAACAGCAGACGGTCTACTGAGGCGAC 
SUMO2 ORF primer 
attB_SUMO2-OSR TGGGTCGCCGTAGACCGTCTGCTGTTGGAA 
attB_SUMO2ΔGG_R 
GCTGGGTCGCCTCAGTAGACCGTCTGCTGTTGGAA 
SUMO2ΔGG mutation 
reverse primer 
attB_ΔCnA-F GCTGGCACCATGTCCGAGCCCAAGGC 
ΔCnA ORF primer 
attB_ΔCnA-OSR GCTGGGTCGCCGTTTCTGATGACTTCCTTCCGG 
attB_CnA-F GCTGGCACCATGTCCGAGCCCAAGGC 
wt-CnA ORF primer 
attB_CnA-MSR GCTGGGTCGCCTCACTGGATATTGCTGC 
attB1 adapter GGGGACAAGTTTGTACAAAAAAGCTGGCACC adapter for full length 
attB-Fragments attB2 adapter GGGGACCACTTTGTACAAGAAAGCTGGGTCGCC 
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Table 4: Oligonucleotide primers for annealing and ligation into pCDNA.6.2/GW-miR Vector for 
expression of micro RNA’s in mammalian cells or shuttling into Destination vectors via gateway shuttling. 
Primer Name Sequence 5' -> 3' Description 
Block-iT_miR-S2_Top 
TGCTGATTGGTTGCCCGTCAAATCGGGTTTTGG
CCACTGACTGACCCGATTTGGGGCAACCAAT 
Micro RNA sequence against 
SUMO2 
within the Block-iT® system by 
Invitrogen 
Block-iT_miR-S2_Bot 
CCTGATTGGTTGCCCCAAATCGGGTCAGTCAGT
GGCCAAAACCCGATTTGACGGGCAACCAATC 
Block-iT_miR-Neg_Top 
GAAATGTACTGCGCGTGGAGACGTTTTGCCACT
GACTGACGTCTCCACGCAGTACATTT 
Scrambled micro RNA 
sequence  
with no specificity for 
mammalian genes 
Block-iT_miR-Neg_Bot 
AAATGTACTGCGTGGAGACGTCAGTCAGTGGCC
AAAACGTCTCCACGCGCAGTACATTTC 
 
 
 
Table 5: Primers for gene quantification via quantitative real-time PCR (qRT-PCR) 
Primer name Sequence 5' -> 3' Description 
qRT-SUMO2_F CCGATTTGACGGGCAACCAATCA 
qRT-Primers for Sumo2 
qRT-SUMO2_R ACACCTCCCGTCTGCTGTTGGA 
qRT-CnA_F CCCAGTCACAGTTTGCGGG qRT-Primers for ppp3ca 
(Calcineurin A) qRT-CnA_R GAGGTAGCGAGTGTTGGCAG 
Rpl32_F CTGCTGATGTGCAACAAATCT qRT-Primers for Rpl32 
housekeeping / control) Rpl32_R GCTGTGCTGCTCTTTCTACAAT 
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Table 6: Oligonucleotide primers for gene quantification via Multiplex quantitative real-time PCR (qRT-
PCR). 
Primer name Sequence 5' -> 3' Description 
Nppa_F GGAGCAAATCCTGTGTACAGTG 
Multiplex Primer and probe labeled  
with dye and quencher for Nppa 
Nppa_R ACCTCATCTTCTACCGGCAT 
Nppa_probe 
FAM-TGATGGATTTCAAGAACCTGCTAGACCA-
BHQ1 
Nppb_F ACAAGATAGACCGGATCGGA 
Multiplex Primer and probe labeled  
with dye and quencher for Nppb 
Nppb_R AGCCAGGAGGTCTTCCTACA 
Nppb_probe HEX-TCAGTGCGTTACAGCCCAAACGA-BHQ1 
Rpl32_F CTGCTGATGTGCAACAAATCT 
Multiplex Primer and probe labeled  
with dye and quencher for rpl32  
(housekeeping/control) 
Rpl32_R GCTGTGCTGCTCTTTCTACAAT 
Rpl32_probe 
Texas Red-
ACTGTGCTGAGATTGCTCACAATGTGT-BHQ2 
Rcan1_fw TAGCTCCCTGATTGCTTGTG 
Multiplex Primer and probe labeled  
with dye and quencher for rcan1-4 
Rcan1_rev GGATTCAAATTTGGCCCTGG 
Rcan1_probe 
Cy5.5-ACGATGATGTCTTCAGCGAAAGTGAGAC-
Eclipse 
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5.1.6 Plasmids 
pDonR 221      Invitrogen 
pcDNA-DEST40     Invitrogen 
pAd/CMV/V5-DEST     Invitrogen 
pcDNA3.1      Invitrogen 
5.1.7 Viruses 
Table 7: Adenoviral constructs used for the overexpression of the depicted constructs in neonatal rat 
ventricular cardiomyocytes. 
Virus Name Description 
AdSUMO2 Overexpression construct, wild type 
AdSUMO2GG Overexpression construct, sumoylation-deficient 
AdRenilla-Luc Overexpression construct, housekeeping control 
AdNFAT-RE Luc NFAT-activation response expression construct 
AdCnA Overexpression construct, wild type 
AdΔCnA Overexpression construct, constitutively active 
AdmiR-SUMO2 micro-RNA expression 
 
5.1.8 Kits  
Block-iT™ Pol II miR RNAi -   Invitrogen 
Expression Vector Kit 
ECL-Select detection system   GE Healthcare 
Nucleo Spin Plasmid Kit   Macherey-Nagel 
Platinum SYBR Green qPCR SuperMix Invitrogen 
Qiagen PLUS Plasmid Midi Kit  Qiagen  
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QIAquick Gel Extraction Kit   Qiagen 
Quikchange II-XL Mutagenesis Kit  Agilent Technologies 
Superscript III First Strand Kit  Invitrogen 
5.1.9 Buffers and solutions 
ADS-Buffer 10x 
 1.16 M  NaCl 
 197 mM  HEPES 
 94 mM  NaH2PO4.H2O 
 55.5 mM Glucose 
 53.6 mM KCl 
 8.3 mM MgSO4, pH 7.4, sterile filtration 
RIPA lysis buffer 
 50 mM  Tris-HCL 
 pH 7.5  titrate with 1 M NaOH 
 150 mM  NaCl 
 0.5 % (w/v) Sodium Deoxycholate 
 1 % (v/v)  NP-40 
 0.2 %   SDS 
NLB (Native Lysis Buffer) 
 50 mM  Tris-HCL 
 pH 7.5  titrate with 1 M NaOH 
 150 mM  NaCl 
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 1 mM  EDTA 
 5 % (v/v)  Glycerol 
Addition of Inhibitors prior to harvest (For NLB and RIPA): 
 Add to 1 mL of lysis buffer: 
 40 µl  25x Proteinase-Inhibitor-Cocktail 
 10 µl  Phosphatase-Inhibitor 2 
 10 µl  Phosphatase-Inhibitor 3 
 1 µl  1 M DTT 
Running buffer, SDS-PAGE (10x) 
 250 mM Tris 
 1.9 M  Glycine 
 1 % (w/v) SDS 
PBS 
 137 mM NaCl 
 2.7 mM KCl 
 4.3 mM Na2HPO4 
 1.47 mM KH2PO4, pH 7.4, autoclaved 
Laemmli buffer (4x) 
 250 mM Tris pH 6.8 
 5 % (w/v) SDS 
 40 % (v/v) Glycerin 
 0.005 % (w/v) Bromophenole blue 
 10 % (v/v) 2-Mercaptoethanol 
Collecting gel buffer 
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 0.5 M  Tris-HCl, pH 6.8 
TBS 
 100 mM Tris-Cl, pH 7.5 
 0.9 % (w/v) NaCl 
Transfer buffer 
 20 % (v/v)  Methanol 
 25 mM  Tris 
 192 mM Glycine 
 0.037 % (w/v) SDS  
Separating gel buffer 
 1.5 M  Tris, pH 8.8 
Trypsin-EDTA solution 
 0.25 % (w/v)  Trypsin 
0.53 mM  EDTA  
In PBS. 
5.1.10 Media 
LB-Medium (Luria-Bertani) 
 1 % (w/v) Tryptone 
 0.5 % (w/v) Yeast-extract 
 1 % NaCl 
 Titration to pH 7.0 with NaOH  
Growth medium (NRVCM) 
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 DMEM with 4.5 g/L Glucose and 110 mg/l Sodium pyruvate 
 10% (v/v) FCS Gold  
(No FCS in media starting from 24 h of culture) 
 100 U/L  Penicillin G 
 100 µg/ml Streptomycin 
 2 mM  L-Glutamine 
Growth medium (C2C12-NFAT) 
 DMEM with 4.5 g/L Glucose and 110 mg/l Sodium pyruvate 
 10 % (v/v) FCS Gold  
 100 U/L  Penicillin G 
 100 µg/ml Streptomycin 
 200 µg/mL Hygromycin B 
 2 mM  L-Glutamine 
Growth medium (HEK293-A) 
 DMEM with 4.5 g/L Glucose and 110 mg/l sodium pyruvate 
 4 % (v/v) FCS Gold 
 100 U/L  Penicillin G 
 100 µg/ml  Streptomycin 
 2 mM  L-Glutamine 
5.1.1 Bacteria 
DH10B, electro-competent   Life-Technologies 
OneShot TOP10, electro-competent  Life-Technologies 
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5.1.2 Cell lines 
HEK293-A 
Human embryonic kidney cells, adenovirally transformed, stably expressing Adenovirus Type 
5 Genes E1 and E3 among others and the SV40 large T-antigen for episomal replication of 
SV40 promoter-containing plasmids. 
C2C12-NFAT 
C2C12 myoblasts were stably transfected using the “pHTS-NFAT” (Biomyx Technology) 
reporter vector carrying a luciferase expression cassette under control of four NFAT enhancer 
sites and an additional Hygromycin selection marker (Frey et al., 2008). 
5.1.3 NRVCM 
Neonatal rat ventricular cardiomyocytes, a primary cell line from 1-3 day old neonatal rat 
ventricles. Cultivation of these cells is explained in detail in the methods section. 
5.1.4 Animals 
New born rats for obtaining hearts for primary cell culture of NRVCM. 
Adult Wistar rats were ordered from the company Charles-River and bred in the central animal 
facility of the University Hospital of Kiel, UKSH. 
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5.2 Methods 
5.2.1 Microbiological methods 
5.2.1.1 Generation of electro-competent bacteria 
For transformation via electroporation, bacteria are needed that are able to uptake plasmids 
from the culture media after application of high voltages. Therefore 50 mL of LB-medium with 
E. coliDH10B bacteria are pre-incubated overnight at 37°C at 200 rpm in an incubator. The 
next day, 1 L of pre-warmed LB-Medium was inoculated with the overnight culture to gain an 
OD600 of 0.1. This culture was then incubated at 37°C and 200rpm until an OD between 0.4 
and 0.8 was measured (~2 h). Rapid cool down of the culture in an ice and water bath was 
carried out and after that, bacteria were pelleted in a centrifuge at 4 °C for 15 minutes at 
11000 g. The pellet was then washed in ice-cold, autoclaved ddH2O and centrifuged. Two of 
those washing-steps were carried out. After the second washing, the pellet was re-suspended 
in 250 mL 10 % (v/v) glycerol in ddH2O and centrifuged as before. The pellet was then re-
suspended in 1.5 mL 10 % (v/v) glycerol in ddH2O and aliquoted in autoclaved tubes in a 50 µL 
scale and frozen to -80 °C on dry ice immediately. Transformation efficiency was determined 
by separately transforming three of the stocks with a control plasmid as described below and 
spreading 1/100 of the reaction onto a 100 µg/mL ampicillin containing LB-Agar plate. 
Overnight cultivation at 37 °C and counting of yielded clones determined the efficiency. 
5.2.1.2 Electroporation 
Electro-competent E. coli bacteria were thawed on ice for five minutes. About 5 ng of Plasmid-
DNA was added directly to the bacteria and the suspension was carefully mixed by pipetting 
up and down. The mix was transferred into a pre-chilled (-20 °C) electroporation-cuvette and 
transformed at 2.5 kV, 200 Ω und 25 µF. After the electric pulse, 1 mL of LB-Medium was 
added to the bacteria and transferred into a new, autoclaved reaction tube. The transformed 
bacteria were incubated at 37 °C for 1 h in a thermomixer at 700 rpm. A portion of the incubated 
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bacteria was then plated onto LB-Agar containing the appropriate antibiotic for selection of 
successfully transformed containing E. coli. 
5.2.1.3 Agar plate preparation 
LB-Medium was prepared with the addition of 1.5 % (w/v) agar. After autoclaving the solution 
it was cooled down in a water bath to 55 °C. The respective antibiotic was added at that 
temperature to prevent structural breakdown. Instead of ampicillin the substitutable antibiotic 
carbenicillin was used at a concentration of 100 µg/mL. Kanamycin and spectinomycin were 
used at concentrations of 50 µg/mL. The warm, antibiotic containing solution was then casted 
into 10 cm petri dishes under a sterile hood. Cooled-down agar plates were stored at 4 °C until 
use. 
5.2.1.4 Spreading of bacteria cultures 
Transformed bacteria were spread onto agar plates employing 4-6 sterile glass beads and 
vigorous shaking. The volume of electroporation mix depended on the respective plasmid, 
typically 100 µL. Plates with bacteria were then incubated at 37 °C overnight or for 14-16 h. 
Individual colonies were then picked with a pipette tip for further experiments. 
5.2.1.5 Growth of the bacteria in liquid-culture 
To the desired amount of LB-medium the appropriate antibiotic was added at the above 
mentioned concentrations. Single colonies picked with a pipette tip or low µL amounts of liquid 
bacteria in culture were inoculated to the LB-medium and incubated at 37 °C and 200 rpm 
horizontal shaking over night or for 14-16 h. 
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5.2.2 Cell culture methods 
5.2.2.1 Culture of mammalian Cells 
All cell culture operations were performed under a sterile hood, separately for each cell line to 
avoid cross-contamination of the cells. Cells were incubated in a 37 °C incubator with 5 % CO2. 
5.2.2.2 Coating of cell culture dishes with bovine collagen I 
All culture dishes and flasks to be used for the culturing of NRVCM had to be coated with 
collagen I prior to seeding the cells. Therefore a collagen I stem-solution (3.1 mg/mL) was 
diluted to a concentration of 50 µg/mL. Dished were coated with 5-10 µg/cm² collagen I solution 
for at least 1 h at RT or overnight. After two washing steps with sterile ddH2O the plates were 
air-dried and stored at 4 °C until usage. Plates were stored for no longer than 7 days. 
5.2.2.3 Primary culture of neonatal rat ventricular cardiomyocytes 
This protocol describes the procedure for the purification and culturing of 40 hearts. For the 
generation of primary cultures from neonatal rat left ventricles, about 40 neonatal rats were 
sacrificed per preparation. After short immerse in 75 % ethanol solution, the rats were rapidly 
decapitated with scissors. An incision of about 2cm into the thorax was made left of the 
sternum. Under application of mild pressure on the abdomen, the heart was taken out and 
immediately placed in ice-cold ADS-buffer. The atria were removed and ventricles moved into 
fresh ice-cold ADS buffer. After removal of the buffer, the ventricles were dissociated with 
scissors until only small pieces of connected tissue were visible. The tissue was transferred 
into digestion-solution. This solution contains 0.5 mg/µL collagenase type 2 and 0.6 mg/mL 
pancreatin in ADS buffer and was sterile-filtered and heated to 37°C prior to use. Digestion 
took place at 37°C in a water bath at 40 rpm horizontal shaking. After 20 minutes, the 
supernatant was removed and discarded. Fresh digestion-solution (1 mL per heart) was added 
and incubated for 20 minutes. The supernatant containing single cells was further processed 
and to the remaining tissue, fresh digestion-solution was added and further incubated until the 
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tissue was dissociated completely. The supernatants were pipetted through a cell-strainer into 
a 50 mL reaction tube and 8 mL of new born calf serum (NCS) was added to inactivate 
collagenase and pancreatin. The solution was then centrifuged at 1000 g, the supernatant 
discarded and the cells resuspended in 5 mL NCS and stored at 37°C in an incubator until 
further use. After four to five of these digestion steps, the pooled and in NSC resuspended 
cells were centrifuged, pelleted and resuspended in 50 mL ADS buffer. 
This solution contains cardiomyocytes along with fibroblasts, blood-cells and other types of 
cells found in the heart an needs to be purified. Therefore cells were separated by their density 
over a percoll-gradient column (Iwaki et al., 1990). A percoll stem-solution was made from 
27 mL percoll and 3 mL 10x ADS. From this stem-solution, two solutions with high and low 
density were generated. Low-density percoll solution contains 9 mL of stem solution and 11 mL 
ADS buffer. 4 mL of the low density-solution was pipetted into a 15 mL reaction tube. High-
density percoll solution contains 13 mL stem-solution and 7 mL ADS buffer and was added to 
the 15 mL tube by carefully pushing the pipette through the low-density percoll solution and 
pipetting the high-density percoll solution to the bottom of the tube. For column-integrity it is 
crucial to pipette the solution very slowly and avoid pipetting air-bubbles into the mixture. 
Addition of phenol-red dye to the low-density solution allows for visualization of gradient-phase 
separation. 500µL of the cell-solution was carefully pipetted onto one gradient and centrifuged 
at 3000 g and 4 °C for 30 minutes with slow acceleration and deceleration without breaks. 
Cells are separated by their density and three phases of the column are visible. 
Cardiomyocytes travel through the column till the phase-border between low and mid phase 
and can be isolated/removed with a transfer pipette. Fibroblasts are less dense and do not 
travel as far, whereas erythrocytes pellet at the bottom of the tube. The myocytes were 
resuspended and washed twice in 50 mL ADS and centrifuged at 1000 g for 5 min. After two 
washing steps, NRVCM were resuspended in 1 mL cardiomyocytes growth medium and 
counted in a Neubauer Chamber with Trypane-blue staining. Cells were seeded onto different 
plates at various densities for the respective dishes and experiments as depicted in table 7. 
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Table 8: Individual seeding density of neonatal rat ventricular cardiomyocytes in different cell-culture 
plates and dishes. 
Plate-type Experiment type Cells / well mL Medium / well 
10 cm dish Protein isolation 10*10^6 10 
6-Well plate Protein isolation 1*10^6 2 
12-Well Plate RNA isolation 3.5*10^5 1 
12-Well Plate  Luciferase experiment 4*10^5 1 
12-Well Plate with coverslips Immunofluorescence 1.8*10^5 1 
  
NRVCM are seeded and incubated in growth medium containing 10 % FCS for the first 18h of 
culture. For all experiments with NRVCM mentioned in this thesis, the cells were washed with 
warm PBS on the next day and supplemented with FCS-free growth medium for the remaining 
time of culture. 
5.2.2.4 Culture of immortalized cell lines 
5.2.2.5 Culture of cells from liquid nitrogen cell stocks 
Cry conserved cells are stored in liquid nitrogen. Cells are thawed rapidly in a 37°C water bath 
and 1 mL of pre-warmed growth medium is added to the cells. The cell solution is then 
transferred into a T75 cell culture flask containing 8 mL of warm growth medium.  
5.2.2.6 Culture of HEK293-A cells 
HEK293-A cells grow in a monolayer on non-coated plastic surfaces.  
The doubling time of HEK293-A is 36h under optimal conditions. Cells were passaged at 
70-80 % of confluence. Culture medium was removed and cells washed with warm PBS that 
was removed afterwards. Cells were dissociated by addition of 2 mL Trypsin-EDTA solution 
and incubation for 1-2 min at 37 °C until single cells were visible under the microscope. 10 mL 
of growth medium were added to the cell-solution to stop the trypsin activity completely. The 
cells were then centrifuged at 1000 g at RT for 5 min. The supernatant was discarded and the 
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cells were resuspended in warm growth medium. Afterwards the cells were either counted in 
a Neubauer chamber and seeded in the respective plate or - without counting - seeded at a 
ratio of 1:10 into new T175 flasks for maintenance of the cell line. 
5.2.2.7 Culture of C2C12-NFAT cells 
The C2C12 cell line grows in monolayer on non-coated plastic surfaces. It differentiates rapidly, 
forming contractile myotubes and producing characteristic muscle proteins when grown 
confluent and/or supplemented with differentiation medium. All experiments were carried out 
in undifferentiated C2C12 cells, therefor they were not allowed to grow confluent and were 
passaged in the same way as the HEK293-A in a different growth medium containing 
hygromycin for plasmid-carrier selection. 
5.2.2.8 Cryo-conservation of the cell lines 
To generate cryo-stocks of the cells, one T175 flask was passaged as described but finally 
resuspended in media containing 20 % FBS and 10 % glycerol. Cell density should be 1-2*1012 
cells/mL. 1 mL of the cell-solution was pipetted into a cryo-vial and cooled down at 1 °C per 
minute in a freezing-container to -80 °C over night. On the next day, cells were transferred into 
liquid nitrogen for storage. 
5.2.3 Molecular biology methods 
5.2.3.1 Plasmid DNA extraction – Mini preparation 
For extraction of small amounts of Plasmid DNA from 5 mL E. coli DH10B overnight cultures, 
the NucleoSpin® Mini-Preparation-Kit was used. Single clone from agar plates or 5 µL of a 
liquid culture were inoculated into 5 mL of LB-medium containing the appropriate antibiotic. 
Bacteria were cultured overnight as described above. 5 mL of the bacterial culture were 
pelleted at 4 °C and 10.000 g for 15 min. All centrifugation steps in this protocol were carried 
out at RT and 11.000 g in a benchtop centrifuge. The pellet was resuspended in 250 µL of 
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buffer A1 (resuspension buffer). 250 µL of buffer A2 (lysis buffer) was added, mixed and 
incubated at RT for 5 minutes. 300 µL of buffer A3 (neutralization buffer) was added to stop 
the lysis reaction. The solution was then centrifuged for 5 min, the supernatant loaded onto the 
provided silica-membrane column and centrifuged. In this step the plasmid DNA binds to the 
column. The flow-through was discarded and after addition of ethanol-containing washing 
buffer A4 the columns were then centrifuged, flow-through was discarded and the columns 
were centrifuged ‘dry’ for 2 minutes. 22 µL of EB-buffer was pipetted onto the column-
membrane and incubated at 55°C for 3 minutes to support the solving of the Plasmid DNA into 
the EB-buffer. Centrifugation for 1 minute elutes the DNA from the membrane. The final flow-
through contains the plasmid DNA extracted from the bacteria culture. 
5.2.3.2 Plasmid DNA extraction – Midi preparation 
For extraction of small amounts of Plasmid DNA from 5 mL E. coli DH10B overnight cultures, 
the Quiagen Plasmid Plus Purification Midi-Kit was used. Single clones or 5 µL of liquid culture 
were incubated overnight in a 50 mL or 100 mL scale. Bacteria were pelleted in 50 mL reaction 
tubes at 4 °C and 6.000 xg for 20 minutes. 2 mL of buffer P1 is added followed by 2 mL of P2 
(lysis buffer) and then incubated at RT for 3 minutes. For neutralization of the alkaline lysis 
conditions 2 mL of buffer P2 was added and placed into a filter cartridge. After 10 min of 
incubation, a plunger was inserted into the cartridge and the cell lysate filtered through the 
membrane to remove cell debris. To the flow through, 2 mL of buffer BB was added, mixed 
and transferred to the spin column, attached to the vacuum-generator. The solution was then 
sucked through the spin column by applying -300 mbar. Endotoxins were removed by addition 
of 700 µL of ETR buffer to the column and application of vacuum, followed by a washing step 
with 700 µL of ethanol-containing washing buffer PE. For complete removal of buffer residues, 
the column was centrifuged at 11.000 g for 2 min. 200 µL of 55 °C warm EB-buffer was added 
to the column and incubated at 55 °C for 3 min. The column was then centrifuged at 11.000 g 
for 1 min and the plasmid DNA was eluted. 
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5.2.3.3 Agarose gel electrophoresis 
Agarose gel electrophoresis was utilized to separate DNA based on the size of the fragment. 
Therefore a 1 % agarose (w/v) was solved in TAE buffer by cooking the solution for one minute 
in a microwave. The solution was then cooled down to approximately 60°C and supplemented 
with 0.5 µg/mL ethidiumbromide. The solution was casted into the gel-chamber and allowed to 
polymerize at RT for 20 min. A comb was inserted into the liquid solution to create pockets in 
the gel for the samples. After polymerization, the comb was removed and the gel was then 
placed into the electrophoresis chamber, filled with TAE buffer to cover the gel. DNA-containing 
samples were pipetted into the pockets and an electric field at 100 V was applied. The 
negatively charged DNA travels through towards the anode and is separated according to the 
size of the fragment, were large fragments travel slower than small fragments. 
5.2.3.4 Open reading frame (ORF) PCR 
For the amplification of the gene of interest, polymerase chain reaction was used. Different 
DNA polymerases can be used, depending on the length of the construct, the annealing 
temperature of the primers and also the GC-content. For the experiments shown in this thesis, 
the Platinum® Pfx DNA Polymerase was used, a DNA-dependent DNA-polymerase with 3’-5’ 
exonuclease activity (“proof reading”) to avoid mutations in the amplified construct. The 
standard-reaction mix was modified according to the manufacturer’s manual if needed, varying 
either the salt concentration (MgSO4) or addition of DMSO for an increase of the primer-
annealing temperature range. Typically the PCR was carried out in a 50 µL scale to yield 
enough amplified DNA fragments for extraction from an agarose gel. 
5.2.3.5 Cloning of full length and ΔGG-deletion of SUMO2 
Full-length and ΔGG mutant of mouse Sumo2 were cloned from mouse heart cDNA by using 
the below explained Gateway® system of molecular cloning with the primers listed in Table 3 
for a first PCR, and attBFor and attBRev for a second step PCR. The PCR product was 
recombined into the pDonR221 plasmid using the Gateway technology and then subsequently 
recombined into expression plasmids pcDNA-DEST40 (SUMO2ΔGG-construct) and 
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pcDNA3.1 (full length construct), for expression in C2C12 cells or into pAd/CMV/V5-DEST for 
adenoviral expression in NRVCM. 
5.2.3.6 DNA extraction from agarose gels 
DNA that was separated via agarose gel electrophoresis can be isolated and purified from the 
gel. The QuiaQuick® Gel-extraction system was used. Therefore the ethidiumbromide-stained 
DNA in the gel was visualized under UV-light, cut out with a new scalpel and transferred into 
a 2 mL reaction tube. The sample was then weighed and three times the volume of the gel-
slice QG-buffer was added to the tube (e.g. 100 µL for every 0.1 g of gel). The gel-slice was 
then incubated at 55 °C for ten minutes or until the gel had dissolved completely. The solution 
was transferred into a spin-column containing a silica-membrane for DNA binding 500µL 
portions at a time and subsequently centrifuged at 11.000 g for 1 min each. Finally another 
500 µL of fresh QG-buffer was added to the column and centrifuged. The flow-through was 
discarded for each of the steps. The columns were then washed with 600 µL of ethanol 
containing PE buffer by centrifugation. Residual buffer was removed by centrifuging at 
11.000 g for 2 min. Addition of 22 µL EB-buffer allows for elution of the membrane-bound DNA 
in another centrifugation step. 
5.2.3.7 DNA and RNA concentration measurement 
DNA and RNA concentration was determined with the NanoDrop™ photometer. Optical 
density was measured at 260 nm and 280 nm and concentrations automatically calculated for 
DNA or RNA respective to the used diluent. Measurements were carried out in duplicates an 
the mean concentration determined 
5.2.3.8 Molecular cloning using Gateway®-technology 
For the cloning of open reading frames or micro-RNAs, I utilized the Gateway®-System that 
uses a recombination-system from the bacteriophage λ, which can enzymatically integrate 
genomic regions into the genome of E. coli. The reaction is site specific and reversible. As a 
first step, the gene of interest is amplified via ORF-PCR from a cDNA pool of the desired 
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species (e.g. cDNA isolated from mouse, human or rat tissue), using primers that contain 
partial attB1 and attB2 flanking sequences. This yields cDNA copies of the open reading frame 
of interest flanked by the specific parts of the attB-sequences. In a second PCR, the first 
product was used as a template and amplification was carried out with primers containing the 
full attB1 and attB2 sequences using the same conditions as for the ORF PCR. This generates 
copies of the ORF of interest flanked by the full-length attB sites. 
These flanked constructs were then recombined into the specific donor (DONR) vector with 
the BP Clonase ® II by incubating 150 ng of PCR-product along with 150 ng of pDonR221 
vector, 1 µL of BP Clonase II in a reaction volume of 10 µL overnight at RT. This enzyme is 
able to cut out regions flanked by specific regions called attP and replace them with attB 
flanked sequences. This step allows the integration of the generated ORF sequences into the 
pDonR221 vector. The generated flanking sites are called attL-sites (attB-insert + attP-vector 
 attL vector). Similar to this step, the shuttling of the sequence of interest from pDonR to a 
destination (DEST) vector is carried out with another enzyme, the LR Clonase ® II. This 
enzyme catalyzes the recombination between attL and attR sites. The insert-carrying pDonR 
and the destination vector are recombined by the Clonase in the same way than the BP 
Clonase reaction was prepared to yield the destination vector constructs containing the 
sequence of interest. 
The empty vectors contain a resistance for specific antibodies for selection of plasmid-carrying 
bacteria after transformation as well as a ccdb-gene (“suicide cassette”) that is only removed 
when the gene of interest or micro RNA is recombined into the plasmid. All generated plasmid-
constructs were amplified in E. coli, DNA isolated and sequenced to assure insertion of correct 
and unmutated sequences. 
5.2.3.9 Generation of artificial micro-RNA constructs using the Gateway®-
compatible Block-iT system 
For the cloning of micro RNAs, the Block-iT RNAi-designer by Invitrogen was used to generate 
target-specific miRNAs flanked by specific sequences that allow formation of hairpin-structures 
and subsequently correct processing of the miRNA in the mammalian cell.  
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Therefore the generated oligonucleotides with 3’ and 5’ overhangs were annealed in 10x oligo-
annealing buffer and ligated into the linear pcDNA6.2-GW/miR vector via T4 DNA ligase 
(1 U/µL). The insertion into the vector is next to a polymerase II promotor sequence that is 
flanked by the attB1 site, generating an attB site flanked, Pol II promoter and miRNA sequence. 
The so generated plasmid is then transformed into E. coli OneShot® TOP10 bacteria, since 
DH10B have a natural spectinomycin resistance which is the selection marker of the pcDNA6.2 
vector. Thus, only TOP10 bacteria carrying the plasmid will survive the spreading on 
spectinomycin (50 µg/mL) containing agar plates. Plasmids were amplified in bacteria as 
described before. The shuttling into a donor and subsequent destination vector is carried out 
by BP Clonase® II and LR Clonase® II as described. 
5.2.3.10 RNA extraction from cells grown in vitro 
Total RNA was isolated from cultured cells using QIAzol lysis reagent. 1 mL of QIAzol was 
added to each well of twice washed cells after removing the PBS. Cells were further lysed by 
pipetting up and down and the solution then pipetted into a fresh 1.5 mL reaction tube. 200 µL 
of chloroform was added and the solutions mixed by inversion of the tubes. The reaction was 
then centrifuged at 15.000 g for 15 min at 4 °C to separate the phenolic and the aqueous 
phase. The RNA-containing aqueous phase was carefully removed with a pipette without 
disturbing the interphase and placed in a fresh, RNAse and DNase free reaction tube. 500 µL 
of Isopropanol was added and the DNA precipitated for 30 min at RT. The precipitated DNA 
was centrifuged down at 17.500 g for 20 min and the supernatant carefully decanted. The 
pellet was washed with 1 mL of 75 % ethanol and centrifuged down for 5 min at 15.000 g. The 
supernatant was decanted and the pellet was air-dried for 5-10 min. The DNA was then solved 
in DEPC-treated, RNAse and DNase free water and concentration determined via NanoDrop 
photometer. 5 µg of RNA were DNase I digested in a reaction mix of 50µL containing 5 µL of 
DNase I and 5 µL of DNase 1 buffer for 15 min at RT to disintegrate any DNA that contaminated 
the RNA preparation. The DNase I was then precipitated by addition of 50µL of a 25:24:1 
phenol-chloroform-isoamylacohol solution and centrifuged at 17.500 g for 10 min. The 
supernatant was pipette into a fresh RNAse-free reaction tube and 300 µL of 99.99 % ethanol 
was added together with 10 µL of 3 M sodium acetate. Precipitation of the RNA occurred at -
20 °C for 30 min and afterwards the samples were centrifuged at 17.500 g for 40 min at 4 °C. 
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The supernatant was discarded and the pellet washed with 500 µL of 75 % ethanol. After 
another centrifugation at 17.500 g for 5 min at 4 °C the pellet was air-dried for 5-10 min and 
solved in an appropriate amount of RNAse-free H2O (approximately 25 µL H2O for RNA from 
1 Well of a 12-well-plate). 
5.2.3.11 Generation of cDNA from RNA samples 
One µg of DNA-free total RNA was transcribed into cDNA using the Superscript III first strand 
cDNA synthesis kit. Therefore the DNA was diluted in a total volume of 13 µL RNAse and 
DNase free water containing 250 ng of random-hexamer primers and 0.5 µL of 10 mM dNTPs 
(2.5 µM of each: desoxy adenosine, desoxy thymine, desoxy guanine and desoxy cytosine) 
and denatured for 5 min at 65 °C in a PCR-cycler. The master mix for the RNA-dependent 
DNA-polymerase was prepared for a volume of 7 µL for each reaction containing 4 µL of 5x FS 
(First strand) buffer, 1µL of 0.1 mM DTT, 1 µL RNAseOUT RNase inhibitor and 1 µL of 
SuperScript III DNA Polymerase. To the denatured RNA, 8 µL of master mix was pipetted and 
placed into a Thermocycler for the synthesis of cDNA. Cycling conditions were 10 min at 25°C, 
1 h at 50 °C, 15 min at 70 °C and then cooled down to 4 °C on hold. The approximate synthesis 
of 1 µg of cDNA was then diluted 5-fold to a final approximate concentration of 2 ng/µL cDNA 
which was then further analyzed by qRT-PCR. 
5.2.3.12 RNA extraction from tissue samples 
To harvest RNA from whole mouse hearts, the tissue had to be broken down using the 
Precellys® 24 homogenizer. The hearts were placed in reaction tubes and 1 mL QIAzol lysis 
solution was added along with plastic beads and placed in the homogenizer. The 
homogenization program used, depended on the size of the hearts and was either 2 x 20 s at 
speed 5000 or 2 x 15 s at speed 6500 until complete dissociation of the tissue. The dissolved 
tissue was then centrifuged at 12.000 g for 20 min and the supernatant placed into a fresh 
1.5 mL reaction tube. The RNA-extraction with subsequent cDNA synthesis was carried out as 
described for cell-culture based RNA extraction. 
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5.2.3.13 Quantitative real-time PCR 
For the quantification of genes, the Platinum® SYBR® Green qPCR Supermix-UDG was used. 
SYBR Green binds to the newly amplified DNA and raises a signal proportional to the amount 
of cDNA in the reaction. The dye is then excited with a laser and its emission is measured and 
automatically detected by the PCR-cycler. Therefore 18 µL of a master mix for each sample 
were prepared, containing 10 µL Platinum® SYBR® Green qPCR Supermix, 0.4 µL of 
Forward+Reverse Primer (10 µM each) and 7.6 µL of DNase-free H2O. The master mix was 
pipetted into the wells of the real-time PCR plate and 2 µL of cDNA (4 ng) was added. After 
sealing the plate with adhesive foil, the samples were spun down and measured in the qRT-
PCR cycler. Cycling conditions are: 3 minutes at 95°C, followed by 40 cycles of (15 seconds 
at 95°C and 45 seconds at 60°C, a common step for annealing and extension at which step 
the fluorophor was excited and the emission was collected). Rpl32 was used as an internal 
normalization control (Frank et al., 2008). Samples were prepared in hexaplicates and qRT-
measurement was carried out in duplicates for each sample. For the quantification, the 
principle of threshold-cycling was utilized were the threshold is the first value that is significantly 
higher than the background. 
5.2.3.14 Protein extraction from tissue samples 
To harvest Protein from whole mouse hearts, the tissue was broken down using the 
Precellys® 24 homogenizer. The hearts were placed in reaction tubes and 1 mL of lysis buffer 
was added along with plastic beads and placed in the Precellys. The homogenization program 
used depended on the size of the hearts and was either 2 x 20 s at speed 5000 or 2 x 15 s at 
speed 6500. The dissolved tissue was then centrifuged at 12.000 g for 20 min and the 
supernatant placed into a fresh 1.5 mL reaction tube. The protein concentration was measured 
by DC™-Protein concentration measurement assay. 
5.2.3.15 Protein extraction from cell culture 
The cell culture media is removed and cells are washed with ice-cold PBS twice prior to 
addition of the lysis buffer containing protease and phosphatase inhibitor cocktails. Plates are 
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then directly placed on ice and incubated for 15 min. From this step on, the protein is constantly 
kept at 4 °C or on ice. The cells were scraped off with a cell-scraper and transferred into a 
reaction tube. NRVCM were further lysed by 3 freeze-thaw cycles from -80 °C to 4 °C. The 
solution was then centrifuged at 12.000 g for 20 min and the supernatant carefully transferred 
to a fresh tube without disturbing the pelleted cell-debris. 
5.2.3.16 Protein concentration measurement using DC protein-assay kit 
For determination of the protein concentration from the above mentioned, harvested protein-
solutions from tissue or cells, the DC™-Protein assay kit was used. Therefor a standard-curve 
with a known protein concentration had to be generated. The stock-solution of 4 mg/mL BSA 
(w/v) solved in the respective lysis buffer was diluted in a way were 6 tubes were filled with 
20 µL of lysis-buffer and to the first tube, 20 µL of the stock was added to obtain a concentration 
of 2 mg/mL. From this tube, 20 µL were pipetted to the next tube until all 6 tubes were serially 
diluted. The stock and protein were pipetted into an appropriate 96 well plate that allowed for 
measurement of the OD at 750 nm. 5 µL of the standard and sample were pipetted into each 
well, 25 µL of provided solution A’ was added, followed by 200 µL of solution “B”. After an 
incubation of 15 min, the samples were measured photometrically and by linear regression of 
the standards, the protein concentration in the samples was measured respectively if in range 
between first and last standard concentration. 
5.2.3.17 Reporter gene assays 
All the reporter gene assays shown in this work were performed either in NRVCM or C2C12-
myoblasts. Cells were infected with combinations of different viruses listed in Table 7 along 
with adenoviruses carrying NFAT-responsive element firefly luciferase and Renilla luciferase 
for normalization of the measurements. Studies were performed in a 12-well-plate format using 
a dual luciferase reporter assay. Therefore the media was removed and cells washed twice 
with ice-cold PBS. 100 µL of passive lysis buffer provided with the kit was added and the plates 
were freeze-thawed twice to -80 °C and then shaken at maximum speed on a horizontal plate 
shaker for 15 min at RT. 20 µL of the cell-lysate was pipetted into one well of a 
chemiluminescence compatible 96-well-plate and placed in the infinite m200 PRO system. 
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Chemiluminescent solutions were automatically injected into the well, where first solution A 
was injected and firefly luciferase derived chemiluminescence was measured. After that, 
solution B was injected that quenched the luminescence of the firefly luciferase, followed by 
the measurement of the Renilla luciferase chemiluminescence measurement. 
5.2.3.18 Co-Immunoprecipitation 
Mouse left ventricles were homogenized as described in 5.2.3.14 in native lysis buffer (NLB). 
Protein concentration was measured with the DC assay (5.2.3.16) and 1 mg of protein diluted 
in a total volume of 1 mL in a fresh reaction tube. Approximately 4 μg of anti-SUMO2+3 
antibody (mouse monoclonal, Abcam) or anti-HA antibody (mouse monoclonal, Sigma, control) 
was allowed to interact with 1 mg of protein for 6 h at 4 °C on a rotating wheel (speed 12), to 
which 50 μl of equilibrated Dynabeads were pipetted. The beads were equilibrated prior to 
usage by adding 1 mL of NLB to 50 µL of beads in a reaction tube and rotating the solution on 
a wheel for 5 min at 4 °C, then placed on a magnetic rack and discarded off the buffer. This 
equilibration step was carried out three times. The IgG-bound proteins were incubated with the 
beads for IgG-to-beads binding overnight at 4 °C. The supernatant was removed after placing 
briefly centrifuged tubes on a magnetic stand. Beads were then washed for 6 times with native 
lysis buffer in the same way as equilibration was carried out. Precipitated proteins were eluted 
by incubating the buffer-free beads with 50 μl of 2x Laemmli buffer for 5 min at 95 °C. Samples 
were spun down in a micro centrifuge and placed on a magnetic rack. The eluted samples 
were pipetted into a fresh reaction tube and the beads discarded. 10-20 μl of the eluted IP-
sample was subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE), followed by 
western-blot transfer to polyvinylidenefluoride membranes and western blotting. 
5.2.3.19 SDS polyaclylamide gel electrophoresis (SDS-PAGE) 
To separate proteins according to their molecular weight, we used a sodium-dodecyl-sulfate 
polyacrylamide gel electrophoresis. SDS is a molecule that stoichiometrically binds to and 
denatures protein chains as well as masking the protein’s charges, creating an overall negative 
charge and therefor allowing the protein to travel along a discontinuous electrical field. The 
SDS-containing samples are separated with the help of a polyacrylamide gel. Therefor the 
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appropriate gel-casting-cassette is set up and filled to ¾ with separating gel containing 8 to 
12 % polyacrylamide. Therefore, separating gel buffer, water and a 37.5:1 acrylamide: 
bisacrylamide-solution were mixed and TEMED and APS were added to aid the polymerization 
and provide free radicals. The cassette is then immediately filled up with isopropanol on top of 
the separating gel to remove any air bubbles and create an even horizon. After 20 min, the 
isopropanol was discarded and the collecting gel containing 4 % polyacrylamide is poured on 
top of the separating gel and a comb, creating 10 or 15 pockets is inserted into the collecting 
gel. After polymerization, the gel-chamber was set up and the combs removed. The pockets 
were then flushed with running buffer and samples could be loaded into the pockets. Alongside 
the samples, a pre-stained marker had to be loaded to determine the range of travel of the 
different size proteins. An electrical field was applied at constant voltage of 120 and the 
proteins separated until the bromphenole-blue from the samples reached the bottom of the 
gel-cassette. 
5.2.3.20 Western blotting 
To transfer the proteins from the polyacrylamide-gel to a polyvinylidenefluoride (PVDF) 
membrane, we used a tank-transfer blotting chamber. The SDS gel is therefore carefully taken 
out of the cassette and set up in the so called “blotting sandwich”. The setup is from bottom to 
top: a sponge, two cellulose filter papers, the SDS gel, the PVDF membrane, two cellulose 
filter papers and a sponge. The PVDF-membrane has to be incubated in methanol for 10 s 
prior to usage. The sandwich has to be set up in the transfer buffer and completely free of air-
bubbles to ensure quantitative transfer of the proteins along the membrane surface. The 
sandwich-containing cassettes are then placed in the blotting-tanks that are filled up with 
transfer-buffer and cooled via -20 °C cold ice-packs inside the tank. An electrical field is then 
applied at constant 380 mA for 90 min. The transfer can be visualized after blotting by 
assessing the transfer of the pre-stained protein ladder that ran alongside the samples and is 
visible on the white PVDF-membrane. The membrane containing the size-separated proteins 
is the placed in 5 % (w/v) dry-milk powder solved in TBS-T buffer and “blocked” for 1-2 h. In 
this step the unspecific protein-binding sites of the membrane are saturated with the protein in 
the milk-powder. 
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5.2.3.21 Detection of specific proteins on a PVDF membrane 
After blocking of unspecific protein binding sites on the membrane, it was incubated in primary 
antibody. Therefore the appropriate antibody that binds to the protein-of-interest’s epitope is 
diluted in 5 % (w/v) dry-milk in TBS-T according to Table 1. The membrane is then rolled up in 
a 50 mL reaction-tube, with the protein-side facing the inside of the tube. A minimum of 3.5 mL 
of the diluted antibody is pipetted into the tube. The membrane was incubated in primary 
antibody overnight at 4 °C on a rotating mixer with integral roles. Afterwards, the membrane 
was washed three times for 10 min in TBS-T buffer and incubated with the secondary antibody, 
coupled to a horseradish-peroxidase (HRP) according to Table 2 for 1 h at RT. After washing 
the membrane trice for 10 min in TBS-T at RT, the membrane was developed using the 
Enhanced-chemiluminescence (ECL) system. This is a method that uses solutions of 
diacylhydrazine luminol and peroxide to obtain chemiluminescence specifically at those sites 
on the membrane, where the HRP-coupled secondary antibody is bound to the protein of 
interest through the primary antibody. The HRP catalyzes the oxidation of the luminol in the 
presence of hydrogen-peroxide resulting in a chemiluminescence at 425 nm that was detected 
with a camera. Therefore the Luminol-peroxide solutions are mixed 1:1, pipetted onto the 
membrane and incubated for 4-5 min in the dark. The residual solution is removed from the 
membrane that is then placed into the detection chamber FluorChem Q. The emitted 
chemiluminescence was detected and densitometrically quantified using the AlphaView Q 
software, provided by the manufacturer. 
5.2.3.22 Generation of recombinant adenoviruses for recombinant    
protein or miRNA expression 
The adenoviruses that were used, were generated using the ViraPower™ Adenoviral Kit. 
Therefore a cDNA that had been previously cloned into the pDonR 221 vector was shuttled 
into the pAd/CMV/V5-DEST Gateway vector and then Pac I digested in a way where 10 µg of 
vector-DNA were incubated with 1x CutSmart buffer and 1 µL of Pac I-enzyme (10 U/µL) in a 
total volume of 50 µL overnight at 37 °C to receive linear DNA. Pac I restriction enzyme 
digested pAd/CMV/V5-DEST constructs were transfected into HEK293-A cells to produce 
protein expressing adenoviruses. The HEK293-A cells provide the genes encoding for the 
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packaging of the viruses and allow for lytic virus-production. Therefore HEK293-A were seeded 
into 6-well-plates on the day prior to the transfection at a density that after 24 h approximately 
70 % of confluence was reached. The cells were then transfected with 1 µg and 2 µg of the 
linear pAd/CMV/V5-DEST vector containing the cDNA of interest. One well was transfected 
with each concentration of vector. The HEK-cells were then incubated for 48 h and the media 
was changed 24 h after transfection. The cells were then trypsinized as described and 
transferred into a T75 flask containing 12 mL of growth media. Every 72h, 50 % of the growth 
media was replaced with fresh, warm growth media to provide sufficient nutrients and buffering 
of the solution. The cells were microscopically checked for virus production twice a day, 
typically after 12 days the cells show a round-up shape and wholes appear in the cell-layer 
with detached cells at the edges. This showed that the virus started to lyse the cells and is 
present in the supernatant. The cells were incubated further until lysis was almost complete. 
The remaining cells were detached from the surface by pipetting up and down and the media 
containing viruses and cells in centrifuged down for 5 min at 1000 g. The supernatant is 
transferred into a 15 mL tube, the pellet resuspended in 1 mL of PBS and further lysed by three 
freeze-thaw cycles as described before. After centrifugation for 5 min at 1000 g, the 
supernatant was pipetted into the 15 mL tube containing the first supernatant. This “lysate 1” 
is then stored at -80 °C until further usage. For the generation of greater amounts of virus 
particles, HEK293-A cells were seeded into T175 flasks and incubated until they reached 
100 % of confluence. 1-3 mL of the lysate 1 is then added to the flasks and incubated to 24-
48 h until the cells show first signs of lytic virus production. Based on the assumption, that 
every cell has been infected by the adenoviruses from lysate 1, the cells were not incubated 
until lysis is complete but detached from the flask and centrifuged down when most of the cells 
still remain their membrane integrity. The supernatant was discarded and the cell-pellet 
containing intact, virus filled cells is resuspended in 2 mL of PBS and lysed by three freeze-
thaw-cycles. After centrifuging for 10 min at 12.000 g and 4 °C, the supernatant was aliquoted 
into fresh reaction tubes in 20-30 µL portions. One of these aliquots was then used for the 
determination of the amount of infectious viruses per µl (ifu/µL). 
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5.2.3.23 Virus particle titration 
Titration of the viruses was carried out by staining infected HEK293-A cells with FITC-labeled 
anti-Hexon antibody. Therefore HEK293-A cells were seeded in a 12-well-format at 3*105 cells 
per well in 1 mL of growth media. Cells were then infected with the adenoviruses produced at 
different concentrations. Therefore a serial dilution of 50 µL of the virus aliquots was prepared 
in 1.5 mL reaction tubes. Dilutions ranged from 10-2 to 10-7 with ten-fold dilution in every step, 
resulting in in 6 different dilutions. One well was not infected, serving as a negative control, 
whereas the first dilution of 10-2 served as a positive control and was only pipetted into one 
well. The remaining dilutions were pipetted into two wells each, each dilution at 50 µL per well. 
The infected cells were incubated at 37 °C for 48 h. The media was removed and the cells 
were fixed with 1 mL -20 °C cold methanol for 10 min at -20 °C. After three washing steps PBS 
containing 1 % BSA, the cells were incubated with 100 µL of the FITC-coupled anti-Hexon 
antibody for each well for 1 h at 37 °C in the dark. After three washing steps with PBS 
containing 1 % BSA the number of infected cells was counted. Therefore the FITC was excited 
under UV-light and the emitted green fluorescence was microscopically observed. Infected and 
thus green cells were counted in ten randomly chosen fields of view with the 20 x objective. 
The mean cells per field of view was calculated. For the 20 x objective, 313 field-of-view can 
be chosen to cover the whole well. The mean number of infected cells was then multiplied by 
313 to approximate the total number of infected cells per well. Division of this number by the 
manifold of dilution multiplied with the amount of virus pipetted into each well yields the 
infectious units per mL (ifu/mL) and is used to maintain a constant amount of infectious virus 
particles between individual virus-stocks and control viruses. 
5.2.3.24 Immunofluorescence 
For immunofluorescence staining, NRVCM were seeded on collagen-coated glass-coverslips 
and grown in DMEM-Medium as described. NRVCM were washed three times with ice-cold 
PBS and fixed with 1 mL 4% paraformaldehyde for 10 min at room temperature and washed 
three times with cold PBS. The cells were then permeabilized and further fixed in 1 mL of -20 °C 
cold methanol at -20 °C and washed three times in cold PBS. The cells were blocked with 1 mL 
of 2.5% BSA in PBS for one hour at room temperature. The coverslips with the attached and 
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fixed cells were then incubated for 90 minutes with primary antibody as listed in Table 1 and 
washed three times for 10 min with PBS at RT. Respective secondary antibodies conjugated 
with fluorescent dyes was added to the cells and incubated for 1 h with the dilutions listed in 
Table 2. The cells were finally washed three times for 10 min in PBS and then mounted on a 
glass slide on 14 µL of mounting-media with the cell-side facing towards the slide. 
Fluorescence images were taken with a Keyence BZ-9000 fluorescence microscope with a 
20x CFI Plan Apo λ lens with an NA of 0.75 at RT. Images taken with the in-built CCD-camera 
were processed and analyzed by BZ-II Analyzer. 
5.2.3.25 Cell surface area measurements 
Cell size measurements were carried out by taking 5x5x5 (x y z) side-by-side 20 % overlapping 
pictures in a 20x magnification. The individual pictures were then merged with the BZ-II 
Analyzer software and a full-focus was generated from the z-stack to create a single, two 
dimensional picture from the multiple pictures taken. The cell size was measured using 
Keyence’s HybridCellCount software module in fluorescence intensity single-extraction mode. 
First, fluorescence-intensity thresholds were set for a reference picture. Therefore α-actinin 
whole-cell staining was set as the target area and the DAPI-stained nuclei were then 
computationally extracted from each target area in order to determine the number of nuclei per 
target area (per cell). Only those cells were taken into the measurement that contained one 
nucleus within one target area. This ensured that only singe cells with one nucleus and no cell-
cell contacts were counted. 
5.2.3.26 Animal housing and experiments 
Animals were housed in the central animal housing at the University Hospital of Schleswig-
Holstein (UKSH) in Kiel. The animals had access to standardized dry-pellet food and water at 
all times and had a cycle of 12 h day and 12 h night. Room temperature was at constant 24 °C ± 
1 °C. Protein samples for the analysis of the SUMO2-expression in animal models of pressure 
overload and hypertrophy, (TAC and Calcineurin-transgene) were provided by Prof. Dr. Frey. 
TAC animals undergo minimal-invasive surgery to constrict their transverse aorta to a defined 
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diameter to increase the afterload of the heart and create constant pressure overload to 
generate a phenotype of cardiac hypertrophy followed by heart failure. 
All applications for animal experiments mentioned in this thesis were approved by the 
government and the animal protection commissary. Individual experiments were carried out in 
strict accordance to the university ethics guidelines to prevent unnecessary harm and suffering 
to the animals. 
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6 Results  
6.1 A screening for calcineurin-NFAT activators 
In order to identify unknown activators of calcineurin-NFAT signaling a cDNA screening 
strategy was devised, utilizing a commercially available human heart cDNA-library with 
approximately 107 primary clones. These clones were diluted to yield individual pools of 
approximately 200 clones each. Each pools was transformed into bacteria and amplified. The 
plasmids were then isolated and transfected into C2C12 myoblast cells, stably carrying an 
NFAT-responsive element driven firefly-luciferase gene in a 24-well format (Figure 4). 
Individual pools were co-transfected with CnA and analyzed for firefly-luciferase activity. A 
cutoff for further investigation of cDNA-pools that showed increased luciferase activity was 
selected and experiments were carried on with those pools of cDNAs that showed comparable 
or more luciferase activity than the positive controls. Transfected cDNA pools that resulted in 
elevated luciferase activity and thus possibly containing calcineurin-NFAT-activating cDNAs 
were further diluted, amplified and transfected in multiple steps to finally reach a dilution of 
approximately 12 cDNA constructs per dilution. After another round of transformation, 
amplification and plasmid preparation, these pools were re-transfected into C2C12 cells in a 
24-well format and analyzed for NFAT-signaling activation. After one additional round of 
dilutions, single clones were transfected and positives were sequenced to identify two possible 
calcineurin-NFAT activating Proteins, SUMO2, a posttranslational modifier and PRP31, a 
protein involved in the assembly of the spliceosome. Further verification was achieved by co-
overexpression of CnA together with a vector carrying SUMO2 or PRP31. Despite the 
promising calcineurin-NFAT-activation of both candidates within the screening conditions, only 
SUMO2 turned out to be a strong activator of the calcineurin-NFAT signaling pathway and was 
thus subjected to thorough characterization to identify a possible mechanism of action. These 
screening experiments were carried out in the University Hospital of Heidelberg in the research 
group of Prof. Dr. Frey. Data sets were provided upon the start of the experiments for this 
thesis and are therefore to be regarded as previous achievements. 
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Figure 4: A screening strategy for calcineurin-NFAT activators. Starting from 107 cDNA-clones from 
fetal human heart serial dilutions were performed and plasmid preparations for transfection of C2C12 
cells, stably carrying NFAT-reporter firefly luciferase. Diluted pools of cDNAs were transfected and 
tested for Calcineurin-NFAT signaling activation through luciferase activity screening. Further dilutions 
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and plasmid preparations were carried out, first giving rise to pools of 200 cDNAs, then 12 cDNAs, until 
single clones could be transfected, screened, and subsequently sequenced for individual Calcineurin-
NFAT activating clones. Shown is an exemplary result of a transfection in a 12 well plate scale with 
transfected pools of 12 cDNAs, where one well of plate 2H showed a significantly increased NFAT-
luciferase activity, compared to the positive control and all other plates and wells. 
6.2 Generation and verification of mammalian expression 
constructs for SUMO2 and calcineurin 
To further validate the data from the screening experiment, a SUMO2 wild-type construct for 
the expression in C2C12 myoblasts was generated, using a mammalian expression vector 
(see materials section for details). SUMO2 was successfully overexpressed on both, protein 
(14-fold, Figure 5A &Figure 5B) and RNA-level (67-fold, Figure 5C). Also a wild type CnA-
construct was generated as well as a truncated mutation lacking the calmodulin-binding and 
autoinhibitory domains, making this mutant constitutively active (ΔCnA, Figure 5D). The 
expression of the truncated protein was confirmed by western blot analysis (Figure 5E) with 
the same antibody that detects endogenous or overexpressed wild type CnA. 
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Figure 5: Generation and verification of mammalian expression constructs for SUMO2 and 
Calcineurin. A, B, western blot analysis showing SUMO2 overexpression, relative densitometry was 
calculated through β-actin equal loading control. C, qRT-PCR analysis of sumo2 mRNA expression with 
overexpressed SUMO2 compared to the empty vector control. D, schematic overview of the wild type 
and truncated CnA expression constructs that were generated. E, western blot analysis showing 
endogenous CnA and ΔCnA overexpression. †: p<0.01, ‡: p<0.001. 
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6.3 SUMO2 activates calcineurin-NFAT-signaling in C2C12 cells 
The activation of NFAT-signaling was reconfirmed by transfecting the cells with NFATc4 or 
SUMO2 in the presence or absence of constitutively ΔCnA and observed a strong activation 
of NFAT-signaling through ΔCnA at baseline conditions as well as a significantly additive effect 
of SUMO2 on NFAT-signaling in the presence of ΔCnA (Figure 6A). To prove a physiological 
relevant interaction, the effect on overexpressed wild type CnA that can be pharmacologically 
activated was also studied. Therefore C2C12 cells were transfected with wild type CnA and 
activated it through addition of Ionomycin and PMA, leading to a robust Calcium influx (Frey et 
al., 2008) and thus to the activation of Ca2+ dependent proteins like CnA (Figure 6B). A strong 
activation of NFAT-signaling through SUMO2 or CnA overexpression was observed at 
baseline conditions (Ctrl) as well as an increased activation of NFAT-signaling in the presence 
of CnA and SUMO when CnA was pharmacologically activated (IONO/PMA). 
A
‡
*
†
‡
N
c4
N
c4
+S
2
0.1
1
10
100
1000
Control
DCnA
R
e
la
ti
v
e
N
F
A
T
-l
u
c
a
c
ti
v
it
y
B
N
c4
+C
nA
N
c4
+C
nA
+S
2
0
1
2
3
4
5
Ctrl
IONO/PMA
R
e
la
ti
v
e
N
F
A
T
-l
u
c
a
c
ti
v
it
y
*
‡
†
‡
‡
 
Figure 6: SUMO2 activates calcineurin-NFAT-signaling in C2C12 cells. A, cells carry functional 
NFAT-responsive element (RE) driven firefly luciferase. ΔCnA is either or not transfected in the presence 
or absence of SUMO2. Shown is the mean of three independent experiments in quadruplicates, 
logarithmic scale for improved differentiation. B, NFAT-responsive element driven firefly luciferase 
activity in the presence of wild-type CnA and NFATc4 and in the presence or absence of SUMO2. CnA 
is either or not activated by Ionomycin (2 µM) + PMA (1 µM) addition. Shown is the mean of two 
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independent experiments in quadruplicates. Statistical calculations were carried out with two-way 
ANOVA *: p<0.05, †: p<0.01, ‡: p<0.001. 
6.4 SUMO2-knockdown reduces calcineurin-NFAT-signaling in 
C2C12 cells 
Next, a potentially essential role of SUMO2 on CnA and hence NFAT-signaling via siRNA 
mediated knockdown of SUMO2 in C2C12 cells was investigated. Transfection of these cells 
with a SUMO2 siRNA led to 85% knockdown on protein- and 78% knockdown on RNA level, 
respectively (Figure 7A, 4B & 4C). Although ΔCnA increased NFAT-signaling compared within 
the control siRNA conditions, upon knockdown of SUMO2 there was significantly less NFAT-
activation compared to control-siRNA (Figure 7D), strengthening the screening-experiment 
derived hypothesis of an important regulatory role for SUMO2 on calcineurin- and 
consequently NFAT-signaling. 
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Figure 7: SUMO2-knockdown reduces Calcineurin-NFAT-signaling in C2C12 cells. A, B, western 
blot analysis showing knockdown of SUMO2 and relative densitometry was calculated through β-actin 
equal loading control. C, expression of sumo2 in the presence of siRNA against sumo2 compared to 
non-targeting control siRNA. D, NFAT-RE firefly luciferase activity in the presence of NFATc4 and in the 
presence or absence of ΔCnA and / or siRNA against sumo2 or control siRNA. Shown is the mean of 
two independent experiments in hexaplicates. All experiments were performed in C2C12 cells stably 
expressing NFAT-RE driven firefly luciferase. Statistical calculations were carried out by two-tailed 
Student’s t-test (B, C) or two-way ANOVA (D). *: p<0.05, †: p<0.01, ‡: p<0.001. 
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6.5 SUMO2 dependent sumoylation is increased in disease 
animal models of pressure overload and hypertrophy 
In order to assess a pathophysiological relevance of SUMO2, the SUMO2-dependent 
sumoylation status in two different mouse models of cardiac disease, calcineurin transgenic 
and TAC operated mice was studied (Molkentin et al., 1998). Calcineurin transgenic mice show 
pronounced hypertrophy followed by heart failure. TAC operated mice suffer from pressure 
overload, resulting in hypertrophy and heart failure. Both animal models display a significant 
increase in monomeric ‘free’ SUMO2 compared to respective control mice (Figure 8A, 5B, 5D 
& 5E). While SUMO2 is involved in many pathways and its covalent attachment to other 
proteins is therefore expected to be differentially regulated, both disease models showed an 
overall increase in protein sumoylation, displayed by a stronger intensity of the bands and a 
‘ladder like’ appearance of the band throughout the whole membrane. The observed increase 
was more prominent in calcineurin transgenic mice, adding evidence for a calcineurin-
dependent effect of SUMO2 (Figure 8A, 5C, 5D & 5F). I observed ubiquitous expression 
pattern of sumo2 in various tissues including lung, liver, kidney, etc. Moreover, sumo2 
expression was relatively higher in the heart compared to the skeletal muscle (Figure 8G) 
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Figure 8: SUMO2 dependent sumoylation is increased in disease models of pressure overload 
and hypertrophy. A, western blot showing SUMO2 expression in wild type (wt) and Cn transgenic mice 
(age: 18 weeks); “free SUMO2/3” shows a shorter exposure band of the above shown monomeric, 
unsumoylated protein-band, upper panel shows the whole membrane. Relative expression of free 
SUMO2/3 (B), and total SUMO2/3 (C) was calculated by densitometric analysis using GAPDH as an 
endogenous control. D, western blot showing SUMO2 expression in sham and TAC operated mice (age: 
8 weeks, following 4 weeks under pressure overload (TAC); “free SUMO2/3” shows a shorter exposure 
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band of the above shown monomeric, unsumoylated protein-band, upper panel shows the whole 
membrane. E, F, Relative expression of free SUMO2/3 (E), and total SUMO2/3 (F) was calculated by 
densitometric analysis using GAPDH as an endogenous control. Statistical calculations were carried out 
by two-tailed Student’s t-test (B, C, D, F) *: p<0.05, †: p<0.01. Dividing lines represent rearrangements 
of respective lanes within one membrane. MRNA levels of sumo2 in different tissue samples from wt 
C57BL/6 mice, normalized to skeletal muscle expression, n=4 mice. 
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6.6 SUMO2 activates Calcineurin-NFAT signaling in NRVCM 
Through our luciferase screen, SUMO2 was identified as a robust activator of NFAT-signaling 
in C2C12 cells, a mouse skeletal myoblast cell line. Therefore it was investigated, whether 
SUMO2 overexpression also effects cardiac NFAT-signaling. An adenoviral construct for 
SUMO2 was generated to be used in NRVCM, which expressed recombinant protein at 
significant levels (Figure 9A & 6B). The “free” SUMO2, running at approximately 18 kDa is 
strongly expressed as well as an increase in overall sumoylation, represented by increased 
streak-pattern throughout the lanes in SUMO2 overexpression conditions compared to LacZ 
control. To reproduce the findings from C2C12 cells, I also generated an adenoviral expression 
construct for ΔCnA and were able to overexpress the protein in NRVCM. Alike previously 
observed in C2C12 cells, overexpression of SUMO2 in NRVCM led to activation of NFAT-
signaling at baseline conditions without further challenging the cells (Figure 9D). The ΔCnA 
mediated increase in NFAT-luciferase activity was further increased when SUMO2 was co-
expressed, resembling our findings from C2C12 and justifying cardiac-specific advance of our 
analyses. 
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Figure 9: SUMO2 activates Calcineurin-NFAT signaling in NRVCM. A, B, western blot analysis 
showing SUMO2 overexpression in the presence or absence of adenoviral (Ad) SUMO2 
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overexpression, relative densitometry was calculated through α-tubulin equal loading control. C, western 
blot showing overexpression of truncated ΔCnA and wild type CnA in the presence or absence of 
overexpressed SUMO2 compared to LacZ control. D, NFAT-RE firefly luciferase construct was 
expressed via adenoviral infection and luciferase activity measured in the presence or absence of ΔCnA 
and SUMO2. Shown is the mean of three independent experiments in hexaplicates. Statistical 
calculations were carried out by two-tailed Student’s t-test (B) or two-way ANOVA (D). *: p<0.05, †: 
p<0.01, ‡: p<0.001. 
6.7 Knockdown of SUMO2 inhibits calcineurin-NFAT signaling 
in NRVCM 
A synthetic miRNA against sumo2 and an adenoviral expression construct for this miRNA were 
generated. I was able to successfully knock down SUMO2 in NRVCM on protein and RNA 
level (Figure 10A & Figure 10B). Then, the effects of a knockdown of endogenous SUMO2 on 
NFAT activation via NFAT-luciferase-RE that was expressed by co-infection along with the 
miRNA constructs was investigated. The effect of a SUMO2 knockdown on NFAT-signaling 
was then investigated at baseline condition, as well as in challenged cardiomyoctes. Two 
doses of NFAT-signaling activator PE, at 1 µm and 5 µM were utilized and led to a dose 
dependent increase of NFAT-luciferase activity at baseline conditions (miR Neg, Figure 10C). 
Along these lines, an induction of Ca2+ dependent signaling, that also activates endogenous 
CnA and subsequently NFAT-signaling, led to an increase in NFAT-luciferase activity 
(Figure 10C). In all conditions the knockdown of SUMO2 resulted in a substantial decrease in 
NFAT-luciferase activity (miR S2, Figure 10C). Moreover, NFAT activation through 
constitutively active CnA leads to a strong expression of Rcan1-4, an exquisitely NFAT-
sensitive gene, the increased expression of which is almost abrogated when SUMO2 is 
knocked down (Figure 10D & Figure 10E). Rcan1-4 expression is already reduced when 
SUMO2 is knocked down at baseline conditions (Figure 10D & Figure 10E, control). Both 
findings further support a necessary role for SUMO2 on calcineurin-mediated NFAT-signaling. 
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Figure 10: Knockdown of SUMO2 inhibits calcineurin-NFAT signaling in NRVCM. A, western blot 
showing SUMO2 knockdown with miRNA against sumo2 (Ad miR S2) compared to negative control 
miRNA (Ad miR Neg) and relative densitometry was calculated through α-tubulin equal loading control. 
B, expression of sumo2 in the presence of miR S2 compared to miR Neg. Shown is the mean of two 
independent experiments in quadruplicates. C, Ad NFAT-RE firefly luciferase activity in the presence of 
miR S2 (96h knockdown) compared to miR Neg in the presence of PE (1 µM or 5 µM) and 
Ionomycin/PMA (2 µM/4.5 nM). Data represented as a mean of two independent experiments performed 
in hexaplicates. All experiments were performed in NRVCM cells. Statistical calculations were carried 
out by two-tailed Student’s t-test (B) or two-way ANOVA (C & E). †: p<0.01, ‡: p<0.001. Dividing lines 
represent rearrangements of respective lanes within one membrane. 
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6.8 SUMO2 induces hypertrophy in cardiomyocytes 
Calcineurin-NFAT signaling is one of the key signaling pathways directly involved in the 
induction of pathological cardiac hypertrophy. Given the strong activation of NFAT-signaling 
that was observed in NRVCM and C2C12 cells, the potential phenotypic and molecular effects 
of SUMO2 in NRVCM was further investigated. Adenoviral overexpression of SUMO2 led to a 
significant increase in NRVCM surface area compared to LacZ control virus infected cells, 
visualized by alpha-actinin staining, resembling the actin cytoskeleton (Figure 11A). Cell size 
was measured in a semi-automated way, whereby pictures of different randomly chosen fields 
of view were taken manually and the cell size measurement was executed via previously 
programmed computed script, equal for all pictures taken. Only cardiomyocytes with one 
nucleus, not in cell-cell contact with others were included, yielding a median cell-size increase 
of about 200 µm² and overall a larger 95th percentile, resembling an increased amount of larger 
cells (Figure 11B). In line with the SUMO2 induced increase in cell size, a significant 
upregulation of the fetal genes nppa and nppb, which are recognized as markers for in vitro 
cardiomyocyte hypertrophy was observed (Figure 11C & Figure 11D). Moreover, the 
expression of rcan1-4, a known NFAT-responsive marker gene, was increased upon SUMO2 
overexpression (Figure 11E). Taken together, these data clearly indicate that SUMO2 
overexpression induces cardiomyocyte hypertrophy, consistent with the robust activation of 
calcineurin-NFAT signaling in vitro. 
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Figure 11: SUMO2 induces hypertrophy in cardiomyocytes. A, representative immunofluorescence 
analysis of fixed NRVCM, overexpressing LacZ or SUMO2 (scale bar 50 µm). B, cell surface area. 
Shown is the analysis of two independent experiments in triplicates with n>1000 counted cells per 
replicate. C, D, E expression levels of nppa, nppb and rcan1-4 respectively in the presence or absence 
of Ad S2. Shown is the mean of two independent experiments in hexaplicates. All experiments were 
performed in NRVCM cells. Statistical calculations were carried out by two-tailed Student’s t-test (C, D, 
and E) or one-way-ANOVA (B). †: p<0.01, ‡: p<0.001. 
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6.9 SUMO2 effects on NFAT-signaling and hypertrophy are 
sumoylation independent 
As sumoylation of proteins is the major mechanism of modification by which SUMO proteins 
exert their structural and/or functional effects and published data on SUMO- proteins largely 
involves sumoylation dependent mechanisms, a sumoylation-deficient SUMO2 mutant was 
investigated. This tentative approach was to determine whether the effects observed for 
SUMO2 are sumoylation-dependent or independent. I therefore created the sumo2ΔGG 
mutant construct via site directed mutagenesis (Figure 12A). The two glycine-residues C-
terminal of the protein are the site of covalent attachment with other proteins, thus our construct 
missing this diglycine motif is unable to attach to other proteins (sumoylation deficient). It was 
cloned into an adenoviral expression vector for overexpression in NRVCM and I was able to 
overexpress SUMO2ΔGG (Figure 12B & Figure 12C). Also the NFAT-reporter mediated 
luciferase assay with SUMO2ΔGG in the presence or the absence of ΔCnA in our starting 
model of C2C12 myoblasts was repeated, for which a mammalian expression vector 
containing the ΔGG construct was created. In presence of overexpressed ΔCnA, the 
sumoylation deficient SUMO2ΔGG leads to a strong activation of NFAT-signaling in NRVCM, 
comparable to overexpressed wild type SUMO2 (Figure 12D). Likewise, in the absence of 
ΔCnA there was no significant difference in the activation of NFAT-signaling between LacZ 
control and SUMO2 and SUMO2ΔGG (Figure 12D). I also repeated the initial NFAT-luciferase 
activity assay (Figure 12D, for C2C12 data) in NRVCM and obtained a similar increase in 
luciferase activity whether SUMO2 or SUMO2ΔGG were overexpressed when compared to 
the empty vector control. There was no significant difference between the two SUMO- 
constructs at baseline conditions, as well as in ΔCnA challenged cells. Finally, SUMO2ΔGG 
overexpression increased NRVCM cell size in the same magnitude as SUMO2 when 
compared to LacZ control (Figure 12F). These observations rule out a solely sumoylation 
dependent mechanism for the SUMO2 dependent activation of calcineurin-NFAT-signaling. 
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Figure 12: SUMO2 effects on NFAT-signaling and hypertrophy are sumoylation independent. A, 
site directed mutagenesis strategy to generate sumoylation-deficient SUMO2-mutant protein 
(SUMO2ΔGG). B, western blot showing overexpression of SUMO2ΔGG compared to LacZ. C, 
densitometric analysis of SUMO2 overexpression normalized to β-actin housekeeper. D, C2C12 cells 
carry functional NFAT-RE driven firefly luciferase, ΔCnA is either or not transfected in the presence or 
absence of SUMO2 or sumoylation deficient SUMO2ΔGG, shown is the mean of three independent 
experiments in quadruplicates. E, NFAT-RE firefly luciferase activity in the presence of either SUMO2 
or SUMO2ΔGG and in the presence or absence of ΔCnA compared to LacZ control. Shown is the mean 
of two independent experiments in hexaplicates. F, cell surface area measurement in the presence or 
absence of overexpressed SUMO2 or SUMO2ΔGG compared to LacZ control. Shown is the analysis of 
two independent experiments in triplicates with n>1000 counted cells per replicate. All experiments 
except for B were performed in NRVCM. For firefly luciferase activity experiments in NRVCM, Renilla-
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luciferase was adenovirally expressed as normalization control. Statistical calculations were carried out 
by two-tailed Student’s t-test (C) or Two-way ANOVA (D, E, and F). *: p<0.05, †: p<0.01, ‡: p<0.001. 
6.10  SUMO2 induces cardiomyocyte hypertrophy via CnA 
A strong impact of overexpressed SUMO2 and SUMO2ΔGG on NFAT-signaling, cell size, 
expression of hypertrophy associated markers like rcan1-4 and fetal genes nppa and nppb in 
the presence of ΔCnA in NRVCM and C2C12 cells was observed. Driven by this evidence, a 
functional interaction between SUMO2 and CnA that induces cardiomyocyte hypertrophy was 
hypothesized that is not solely dependent on sumoylation. In line with this hypothesis, an 
additive increase in cell size when co-overexpressing ΔCnA with SUMO2 or SUMO2ΔGG in 
NRVCM compared to SUMO2 or SUMO2ΔGG alone can be observed (Figure 13A & 
Figure 13B). Similarly, the addition of ΔCnA to SUMO2ΔGG overexpression increases 
expression levels of nppa, nppb and rcan1-4 (Figure 13C, Figure 13D & Figure 13E), very 
similar to the previously observed SUMO2 mediated effects on these parameters. SUMO2 or 
SUMO2ΔGG again exaggerate the increased expression mediated via CnA, further 
strengthening the hypotheses of SUMO2 being an activator of cardiomyocyte hypertrophy, as 
well as the mechanism for this being independent of sumoylation. 
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Figure 13: SUMO2 induces cardiomyocyte hypertrophy via CnA. A, representative pictures of the 
immunofluorescence analysis of fixed NRVCM cells in the presence or absence of overexpressed ΔCnA 
along with overexpression of LacZ (control) SUMO2 or SUMO2ΔGG (scale bar 50 µm). B, respective 
cell surface area, shown is the analysis of two independent experiments in triplicates with n>1000 
counted cells per replicate. C, D, E, expression levels of nppa, nppb and rcan1-4 respectively in the 
presence or absence of overexpressed ΔCnA alongside with overexpressed LacZ (control), SUMO2 or 
SUMO2ΔGG. For C, D, E, shown is the mean of two independent experiments in hexaplicates. All 
experiments were performed in NRVCM cells. Statistical calculations were carried out by two-way-
ANOVA. *: p<0.05, †: p<0.01, ‡: p<0.001. 
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6.11 Cell-size increase, mediated by SUMO2 and SUMO2ΔGG 
relies on CnA function 
To further strengthen the findings of a direct interaction between SUMO2 and CnA, I 
investigated, whether or not the inhibition of CnA by two differently acting pharmacological 
inhibitors would abrogate the observed increase in cell size. Ciclosporin and tacrolimus were 
utilized, both indirectly inhibiting CnA by forming a complex with immunophilins and then 
binding to and inhibiting CnA. SUMO2 and SUMO2ΔGG overexpression, as well as 
phenylephrine stimulation of the cells increased the cell size significantly, similar to the 
previously observed effect. When endogenous CnA is inhibited by either ciclosporin or 
tacrolimus, the increase in cell size in the presence of overexpressed SUMO2 or SUMO2ΔGG 
is abolished or significantly decreased (PE), consistent with the notion that SUMO2 directly 
exerts its effects via CnA (Figure 14). 
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Figure 14: Cell-size increase, mediated by SUMO2 and SUMO2ΔGG relies on CnA function. 
Respective cell surface area of fixed NRVCM-cells overexpressing LacZ (negative control), SUMO2, 
SUMO2ΔGG or stimulated with 10µM Phenylephrine (PE, positive control) for 48h. 10µM of ciclosporin 
or 1 µM of tacrolimus or DMSO as control were added as depicted by “+” below the respective bar. 
Statistical calculations were carried out by Kruskal-Wallis-test. ‡: p<0.001. 
 
 
C
e
ll
s
iz
e
µ
m
²
0
1000
2000
3000
DMSO
Tacrolimus
Ciclosporin +
+
+ - - - -
-
-- -
--
-
- -
- - - -
-
-- -
--
- +
+
+
+
+
+
+
+
+
LacZ S2 S2 GGΔ PE
‡
‡
‡
‡
‡
‡
 
   
Results 
 
 
   86  
  
 
6.12  SUMO2 directly interacts with and tethers CnA to the 
nucleus in cardiomyocytes 
The localization of SUMO2 and CnA within the cell were analyzed next. Adenoviral constructs 
for GFP-ΔCnA, SUMO2 and SUMO2ΔGG, alone or in combination were used. SUMO2 can 
typically be found throughout the cell with predominant localization to the nucleus, whereas 
Calcineurin is mainly localized in the cytoplasmic compartment in unchallenged cells. As 
shown in Figure 15A, CnA was shuttled to the nucleus in NRVCM overexpressing ΔCnA and 
SUMO2 (I, rows 2 & 3), whereas it remained cytoplasmic in cells overexpressing CnA alone (I, 
rows 2 & 3; III, row 2) Specially compelling evidence can be found in row I, where two side by 
side cells are visible with only the upper cell being infected with the SUMO2-containing virus 
and only this cell showing nuclear calcineurin, whereas the other cells shows a retention of 
calcineurin to the cytoplasm. In line with the previous findings, this SUMO2 mediated effect on 
CnA seems to be sumoylation-independent since SUMO2ΔGG also induced activation and 
subsequent translocation of CnA to the nucleus, without any apparent difference compared to 
wild type SUMO2 (Figure 15A, column II). To evidence a direct interaction between SUMO2 
and CnA, a co-immunoprecipitation of endogenous SUMO2 and CnA was performed in C2C12 
cells and in mouse heart tissue using a buffer for native protein isolation. As shown in 
Figure 15B, SUMO2 endogenously interacts with CnA in C2C12 cells and in mouse heart 
lysate under native conditions. The data collected for Figure 15A was obtained in cooperation 
with Prof. Dr. Oliver Müller in the University Hospital of Würzburg, Germany. 
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Figure 15: SUMO2 directly interacts with and tethers CnA to the nucleus in cardiomyocytes. A, 
Representative immunofluorescence analysis of fixed NRVCM-cells overexpressing GFP-ΔCnA in 
combination with SUMO2 (I), SUMO2ΔGG (II), or alone (III) show that CnA is translocated to the nucleus 
in cells overexpressing both, CnA and the respective SUMO construct, whereas it remains cytoplasmic 
in cells overexpressing CnA alone; CnA, green; SUMO2 and SUMO2ΔGG, red; Dapi, blue (scale bar 
50 µm). B, Immunoprecipitation was performed using Dynabeads and Antibodies against HA (sigma, 
control) and SUMO2+3 (Abcam) as explained in methods section. 50µg of input lysate was loaded, 1 mg 
of protein was used for precipitation. For western blotting CnA antibody (BD) was used. 
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7 Discussion 
The heart’s reaction to increased and persisting biomechanical stress is the development of 
cardiac hypertrophy. Initially, this response is physiologic, similar to the changes the heart 
undergoes when challenged with exceptional exercise. In this adaptive hypertrophy, the 
cardiac muscle cells grow to enable an accelerated function, that is an increase in pressure 
build-up and ejected blood volume overall. In cultured cells this increase in cell surface area is 
typically accompanied by the elevated expression of the genes encoding natriuretic peptides 
nppa (protein: natriuretic peptide A) and nppb (protein: bain natriuretic peptide). This 
hypertrophic phenotype in the heart and cultured cells is well reviewed by Dorn and others 
(Dorn et al., 2003). Enduring pressure overload and thus biomechanical stress switches the 
initial adaptive response to a maladaptive process, where the mechanical capacity of the heart 
decreases typically by remodeling of the heart tissue followed by myocardial infarction, chronic 
hypertension or valvular heart disease, among others (Ertl and Frantz, 2005; Frantz et al., 
2009; Pfeffer and Braunwald, 1990; Zwadlo and Borlak, 2005). The aim was to identify new 
signaling pathways and therefore proteins involved in pathologic hypertrophy to possibly lay 
the foundation for the assessment of future therapy options. One of the best-studied signaling 
pathways leading to the development of hypertrophy after biomechanical stress is the 
calcineurin-NFAT signaling axis (van Berlo et al., 2013). Calcineurin is a calcium-calmodulin 
dependent serine-threonine protein phosphatase, that has previously been found to be a pro-
hypertrophic signaling modulator (Molkentin et al., 1998). Extensive knowledge has been 
accumulated over the last 17 years about the role that calcineurin plays in the heart. Yet, 
besides the upstream calcium-calmodulin-axis, to date there are still few direct calcineurin 
activators known. Therefore, in the present study I aimed to identify alternative modulators of 
calcineurin-NFAT signaling and their influence on the development of cardiomyocyte 
hypertrophy. With SUMO2 a strong and direct activator of the calcineurin-NFAT axis was 
identified. This activation could be observed in two different cell types, C2C12 cells, a mouse 
skeletal myoblast cell line and in NRVCM, primary cultured cells from neonatal rat ventricles. 
The effects were first measured via NFAT-driven luciferase reporter and were very similar 
among the two different cell types. Moreover, it was discovered that SUMO2 induces 
 
   
Discussion 
 
 
   89  
  
 
cardiomyocyte hypertrophy in NRVCM and does so in a sumoylation independent manner via 
a direct interaction with CnA. 
The research efforts taken to identify endogenous modulators of calcineurin activity have been 
large, their majority yielding the identification of inhibitory molecules (reviewed in (Frey et al., 
2004; Wilkins and Molkentin, 2004). Calcineurin is mainly activated by a rise of intracellular 
Ca2+ levels. Ca2+ ions bind to calmodulin that in turn induces a conformational change of 
calcineurin associated with displacement of its autoinhibitory domain, rendering the 
phosphatase active. It has been previously reported that a protein termed Dyxin, may act as a 
strong activator of calcineurin-mediated cardiac hypertrophy (Frank et al., 2010). On the other 
hand, a variety of CnA inhibitors have been published. For example the protein Cain, being a 
non-competitive inhibitor for Cn in neurons, whereas AKAP79 directly interacts with and blocks 
calcineurin activity in cardiomyocytes. A family of calcineurin-interacting proteins, calsarcins is 
also crucial for the hypertrophic calcineurin-NFAT pathway, negatively regulating CnA activity 
and thus NFAT activation (Frey et al., 2000). Consistently, calsarcin-1 knockout mice show 
exaggerated hypertrophy following pressure overload in mice (Frey et al., 2008). The two 
pharmacologic agents, ciclosporin and FK506/tacrolimus have been widely used in 
immunosuppressant therapy following organ transplant action and were only later found to 
inhibit calcineurin by binding to endogenous immunophilin proteins, termed cyclophilin A and 
FKBP12, respectively (Liu et al., 1991). This underscores the broad relevance of calcineurin 
mediated signal transduction apart from muscle tissue. Rcan1-4 is another essential 
calcineurin-NFAT modulator and also serves as an endogenous indicator of the activation of 
calcineurin-NFAT signaling (Yang et al., 2000). Rcan1-4 is one of the target genes of NFAT, 
but its precise function is still under debate due to both inhibitory and activator roles which 
have been observed under different experimental conditions (Fox and Heitman, 2005; Sanna 
et al., 2006; Vega et al., 2003a; Vega et al., 2003b). More recently however, employing a 
systems biology approach and using single-cell experimentation in combination with in silico 
simulations, Shin et al have suggested a dose dependent effect of Rcan1-4 as an inhibitor at 
lower levels but as a facilitator at higher expression levels, adding another layer of complexity 
to the regulation of calcineurin (Shin et al., 2011). 
A luciferase mediated screening approach for modulators of specific proteins or signaling 
pathways has led to the identification of protein interactions in the past (Chang et al., 2005). 
Chang and colleagues performed a screening experiment for the identification of Histone-
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deacetylase (HDAC) class II modulators (Chang et al., 2005). They designed a eukaryotic 
expression screen with two different fusion proteins and a Gal4-responsive luciferase to detect 
HDAC-modulating proteins. Therefor the transcription-factor Gal4 DNA binding domain was 
fused to the N-terminus of HDAC5, a class II HDAC as well as the fusion of the two transcription 
activating proteins V16 and 14-3-3. Transfection of these fusion proteins alongside an HDAC5-
kinase modulating cDNA from a eukaryotic cDNA-library would result in an activation of 
luciferase expression by reconstituting a functional Gal4 transcriptional complex when HDAC5-
Gal4 fusion protein could recruit the VP16-14-3-3 fusion protein. Similarly, a screening strategy 
based on an NFAT-reporter mediated firefly luciferase assay to search for yet unknown 
modulators of the calcineurin-NFAT signaling axis was designed. A C2C12 cell line subtype 
was generated, C2C12-NFAT which is a cell line of mouse myotube origin that stably 
expressed an NFAT-responsive element driven luciferase, making NFAT-activation in these 
cells visible through the enhanced expression of a firefly luciferase. This cell line enabled the 
screening approach of the human heart cDNA library, in a way where serial dilutions of this 
library were transfected into C2C12-NFAT cells and expressed in the presence of NFAT-
reporter luciferase and calcineurin.  
Several putative candidates were discovered that activated calcineurin-NFAT signaling, yet 
their activation of this pathway was lower than the positive control, that was set as a threshold 
for individual screening sets. Since the study initially aimed for the identification of activating 
molecules that modulate NFAT-signaling beyond the capabilities of the positive control, those 
low-activating candidates were excluded. After applying this rigorous cutoff filter, only two 
plausible calcineurin-NFAT signaling activators were identified, SUMO2 and PRP31. After 
repetition of the original screening experiment in a larger scale and with single clones, PRP31 
failed to activate the NFAT-signaling in a sufficient manner, leading the focus on the 
investigation of SUMO2 and its calcineurin activation capabilities. 
Here, I discovered SUMO2 to be an activator of the calcineurin-NFAT signaling pathway in 
mouse skeletal muscle cells. C2C12-NFAT cells were utilized for screening and verification 
processes, yet are not cells of cardiac origin as well as they are immortalized cells, reducing 
their ability to gain information about SUMO2’s involvement in cardiac signaling. For this 
purpose the cell-system was changed to neonatal rat ventricular cardiomyocytes (NRVCM), a 
rat-ventricle derived primary cell culture that diminishes the bias from immortalized and non-
cardiac cell lines. The calcineurin-NFAT activating properties of SUMO2 were well verified in 
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NRVCM, furthering the relevance in cardiac signaling in general and particularly for possible 
hypertrophy modulating properties in the heart. Along the same lines, a depletion of the 
available SUMO2 by micro-RNA mediated knockdown resulted in a significant decrease of 
NFAT activation at baseline levels as well as in challenged cells. This is shown when even in 
the presence of strong NFAT-signaling activators like phenylephrine or Ionomycin and PMA, 
the reduction of SUMO2-protein levels decreased the NFAT-signaling activation significantly. 
Consistent with the hypothesis of a direct calcineurin-modulation, Rcan1-4 was also 
downregulated upon SUMO2 knockdown under conditions of constitutive CnA activation, 
which further supports an involvement of endogenous SUMO2 in the calcineurin-NFAT 
signaling pathway. 
SUMO proteins are a family of four in human (SUMO1-4 (Guo et al., 2004; Melchior, 2000)) 
that were discovered in the context of their ability to covalently and reversibly modify their 
target proteins, thereby influencing protein activity, localization and stability. SUMO proteins 
share Ubiquitin’s three-dimensional structure yet only 20% of the amino-acid sequence 
(Bernier-Villamor et al., 2002; Huang et al., 2004; Mossessova et al., 2003). In cardiologic 
research SUMO2 and the other SUMO family members have been found to be involved in 
cellular signaling and disease. For that reason, studying the effect of SUMO2 in the context of 
cardiomyocytes is particularly interesting. An example of an association of SUMOs with cardiac 
diseases in humans was suggested by Kho et al, where they find a link between SUMO1 and 
the regulation of SERCA2a in the context of heart failure, stabilizing the protein and its ATPase 
activity (Kho et al., 2011). In failing hearts though, sumoylation of SERCA2a and general 
SUMO1 levels were greatly reduced (Kho et al., 2011). SUMO1 was the first member of the 
protein family identified and has been extensively characterized (Citro and Chiocca, 2013; 
Matunis et al., 1996; Pichler and Melchior, 2002). Very recently, Gupta and colleagues could 
show that the SUMO-conjugating enzyme UBC9, which is the only know SUMO2-E3 ligase yet 
discovered, is of great importance for protein quality control in cardiomyocytes (Gupta et al., 
2014). Of note, SUMO2 has also been implicated in human cardiomyopathy where diminished 
sumoylation of Lamin A resulted in accelerated cell death. Lamin A is a direct SUMO2 target 
and shows two naturally occurring mutants associated with familial cardiomyopathy, localized 
to a sumoylation consensus-motif around Lysine201 (Zhang and Sarge, 2008). I here show that 
SUMO2 expression and SUMO2-dependent sumoylation is enhanced in two important mouse 
models of cardiac hypertrophy and pressure overload. Calcineurin transgenic as well as 
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transverse aortic constricted mice both show elevated levels of SUMO2 and an overall 
increase in sumoylated proteins compared to their wildtype littermates or sham operated 
animals. In line with the proposed mechanism of SUMO2 acting as a facilitator of Calcineurin-
NFAT signaling, especially in calcineurin transgenic mice, elevated levels of SUMO2 could add 
to NFAT activation even though SUMO2 itself does not seem to regulate calcineurin 
expression levels. 
The two proteins, atrial natriuretic peptide and brain natriuretic peptide are diuretic and 
natriuretic hormones that are produced by the fetal, but also adult heart (Sergeeva et al., 2014). 
Simultaneously, cardiac stress induces a ventricular expression of the encoding genes, nppa 
(atrial natriuretic peptide) and nppb (brain natriuretic peptide). For this reason, Nppa and Nppb 
are generally accepted markers for the hypertrophic response in cell culture (Pikkarainen et 
al., 2003) or for the development of hypertrophy and heart failure in animal models (Sergeeva 
and Christoffels, 2013; Sergeeva et al., 2014). Additionally, rcan1-4 expression (Vega et al., 
2003a) as well as the increase in cell surface area are used as markers for the emergence of 
hypertrophy in cell culture. To additionally support the facilitator effect for SUMO2 on 
calcineurin-NFAT signaling not only elevated expression levels of the hypertrophy associated 
genes nppa and nppb were observed but also of the direct NFAT target rcan1-4. Furthermore, 
these molecular changes were accompanied by an increase in cell surface area when 
overexpressing SUMO2, fulfilling all of the above mentioned characteristics for the incurrence 
of cellular hypertrophy. These effects could be augmented by co-overexpression of 
constitutively active CnA, implying a direct functional interaction between CnA and SUMO2 
that is also supported by the elevated expression levels of rcan1-4. In further support of this 
notion, a direct interaction between CnA and SUMO2 in both skeletal muscle cells and mouse 
heart tissue as visualized by the co-immunoprecipitation experiments was observed. Recently, 
another direct interaction partner for CnA has been identified, also leading to the activation of 
the NFAT-signaling pathway. The plasma membrane Na+/H+-exchanger 1 was found to 
stimulate hypertrophic gene expression in NRVCM via calcineurin (Hisamitsu et al., 2012). 
The majority of SUMO-dependent modulations and modifications published so far are based 
on the sumoylation of target proteins. SUMO is expressed as a precursor protein that has to 
be cleaved in order to be activated through accessibility of two C-terminal glycines (SUMO 
diglycine motif). Apart from the well-studied sumoylation modifications, there has been a recent 
discovery of non-covalent sumo-interaction or –binding motifs (SIM/SBM) (Hecker et al., 2006; 
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Song et al., 2004) which influence their targets, all of which are themselves sumoylated 
proteins (Lin et al., 2006; Minty et al., 2000; Shen et al., 2006; Song et al., 2004). Initially 
intended as a control for functional SUMO2, a construct (SUMO2ΔGG) was designed that is 
missing the diglycine motif and is thus deficient for sumoylation. Surprisingly, this sumoylation-
deficient construct resembled the observed effect of SUMO2 in almost every investigated 
parameter. Expression levels of nppa, nppb and rcan1-4 and the cell surface area was 
elevated and interestingly also the exaggeration of ΔCnA mediated effects on the cell surface 
area was resembled. From these observations, I draw the conclusion that the presented 
mechanism of calcineurin activation is independent of sumoylation of calcineurin. Such 
sumoylation-independent mechanisms of protein activity modulation have been published 
before. These so-called SUMO interacting/binding motifs (SIM/SBM) are subject of research 
and have led to a proposed consensus sequence for non-covalent SUMO-interactions (Seu 
and Chen, 2009; Song et al., 2004). There are several examples of sumoylation independent 
non-covalent functional SUMO1 interactions. For example, SUMO1 inhibits RAD51-mediated 
homologous recombination by interaction with RAD51 (Li et al., 2000). Similarly, SUMO1 
protects against cell death by non-covalent interactions with Fas and tumor necrosis factor 
receptor 1 (TNFR1) (Okura et al., 1996). SUMO1 can also inhibit dynamin-dependent 
endocytosis without a covalent modification of dynamin (Mishra et al., 2004). Lee and 
colleagues have shown that SUMO1 represses apoptosis signal-regulating kinase 1 (ASK-1)-
activation through physical interaction and not through sumoylation (Lee et al., 2005). Similarly, 
SUMO3 can co-activate EBNA2 (Epstein-Barr virus nuclear antigen 2) in the absence of direct 
conjugation to EBNA2 (Rosendorff et al., 2004). Finally, SUMO3 has been found to enhance 
Androgen Receptor (AR) transcription independent of SUMO3’s sumoylation ability and AR 
sumoylation sites in prostate cancer cells (Zheng et al., 2006). Of note, Alontaga and others 
have recently published a method for the utilization of a high-throughput screening assay to 
identify small molecule inhibitors for SUMO1-interaction motifs (Alontaga et al., 2015). 
Applying this method to the identification of SUMO2-interaction disturbing molecules is 
particularly interesting to advance the knowledge about the proposed mechanism as well as 
the investigation of possible therapeutic approaches in the future. However, to the best of my 
knowledge, SUMO2 has not been implicated in any non-covalent, sumoylation-independent 
functional interactions so far. Here, a direct endogenous functional interaction between 
SUMO2 and CnA was demonstrated that could be well correlated with SUMO2-mediated 
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activation of calcineurin-NFAT signaling. As a possible mechanism of action for the SUMO2 
induced activation of calcineurin, I hypothesize a tethering of CnA to the nucleus. 
Nuclear translocation of activated calcineurin has already been reported in failing human 
hearts and this nuclear pool of calcineurin is important in the development of cardiac 
hypertrophy (Burkard et al., 2005). Although the exact role of calcineurin in the nucleus is still 
unknown, it has been hypothesized that it is a transcriptional co-activator through direct 
interaction with DNA-bound NFAT (Heineke and Ritter, 2012). The inhibition of nuclear 
calcineurin import with an artificial import blocking peptide prevents myocardial hypertrophy 
(Hallhuber et al., 2006). With SUMO2, a protein was identified that is directly involved in the 
cytosolic to nuclear translocation and/or a nuclear retention of a pool of calcineurin A, 
suggesting this may represent the mechanism by which SUMO2 induces cardiomyocyte 
hypertrophy and general activation of calcineurin-NFAT signaling. This nuclear-retention of 
calcineurin seems to be independent of SUMO2’s sumoylation capabilities since nuclear CnA 
can be found in cells overexpressing SUMO2 or SUMO2ΔGG but not in the control cells. 
Supporting this hypothesis, bioinformatics prediction of SIM/SBM for CnA reveals a possible 5 
amino acid motif “LFLLR” in close proximity to the proposed nuclear localization site and the 
phosphatase-domain (Ren et al., 2009; Zhao et al., 2014). SUMO2-induced conformational 
change could expose the NLS and possibly explain a shift towards nuclear localization of CnA 
upon SUMO2 overexpression. The understanding of posttranslational modifications like 
sumoylation or the protein-protein interactions through SIM/SBM seems to be of great 
importance for the understanding the molecular mechanism leading to heart failure and cardiac 
hypertrophy. Modulation of these pathways could prove an effective means for altering disease 
development and progression in the future. SUMO2 was found as an interesting candidate for 
the modulation of the calcineurin-NFAT driven cardiac hypertrophy via SUMO-interaction with 
CnA. 
In conclusion, based on an unbiased screening experiment, SUMO2 was linked to increased 
NFAT-activation, the induction of hypertrophy-associated genes, and an increase in 
cardiomyocyte surface area+. Moreover, a direct interaction between SUMO2 and CnA was 
found as well as an involvement of endogenous SUMO2 in the activation of NFAT signaling. 
Surprisingly, similar results for SUMO2 and sumoylation-deficient SUMO2ΔGG were obtained 
in every parameter investigated, which ruled out a sole sumoylation-dependent effect. I thus 
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propose a mechanism where SUMO2 activates cardiac hypertrophy independent of 
sumoylation by direct interaction with CnA, facilitating its translocation to the nucleus.  
Given the relevance of the calcineurin-NFAT axis in a multitude of cells and organ systems, 
the further investigation of this mechanism might be valuable for other fields of research such 
as immunology, where calcineurin plays an indispensable role in the activation of the immune 
response via NFAT and where the pharmacologic inhibition of calcineurin results in 
immunosuppression. This thesis presents a mechanism for the involvement of SUMO2 on a 
major signaling pathway in the heart and implies a multitude of regulatory roles on cellular 
signaling in other organ systems. To clarify a possible role for SUMO2 in the modulation of the 
immune response could be of great value. 
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Figure 16: Schematic drawing of a possible mechanism by which SUMO2 induces cardiomyocyte 
hypertrophy. 
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7.1 Outlook 
The proposed mechanism for a sumoylation-independent activation of calcineurin-NFAT 
signaling by tethering calcineurin to the nucleus is a first step towards the characterization of 
the role of small ubiquitin-related modifier 2 in general and in the context of cardiology in 
particular. To further elaborate this mechanism, the interaction between SUMO2 and 
calcineurin has to be mapped and analyzed. Figure 17 shows a schematic overview of the 
calcineurin protein, indicating two putative SUMO-interaction motifs, one based on the 
consensus sequence for SUMO2 protein-protein interaction sites, the other based on a 
bioinformatics approach. Therefore, mutation-studies have to be carried out to pinpoint the 
location of SUMO2-calcineurin interaction and thus providing evidence for the verification of 
our proposed mechanism. 
Secondly, the role for SUMO2 in the development of pathologic cardiac hypertrophy has to be 
investigated in vivo. One possible approach that does not involve the generation of heart-
specific knockdown or overexpression mouse-models could be achieved by generating 
specific adeno-associated viruses (AAV). AAV subtypes can be specifically modified and 
injected into mouse tail-veins for the tissue-specific expression of a nucleic acid of interest 
(Pleger et al., 2011; Ying et al., 2010). AAV9 specifically targets the heart (and also the liver) 
and can be used to overexpress SUMO2 in the heart of wild-type mice to investigate the 
possible development of a cardiac hypertrophy that would prove SUMO2 to be a sufficient 
inducer of hypertrophy. Similarly, a knockdown of SUMO2 in mice challenged with pressure-
overload and consequent development of hypertrophy could be a useful tool to assess the 
necessity of SUMO2 for the hypertrophic signaling and to investigate possible benefits by the 
modulation of SUMO2 expression levels.  
All these lines of experiments are fundamental for future studies in humans and will need to 
be supplemented by collecting information about the SUMO2 expression levels in samples 
from patients that suffer from cardiac disease. After the verification of a pathophysiologic 
relevance of SUMO2 in the development of disease, the design of specific pharmacologic 
inhibitors for disturbing the calcineurin-SUMO2 interaction could be a useful tool for future 
therapy approaches. 
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Figure 17: Schematic drawing of CnA with nuclear localization site (NLS), nuclear export site (NES) 
and predicted putative sumoylation interaction/binding motifs (SIM/SBM) from both, consensus-motif 
search as well as independent bioinformatically predicted motif. 
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9 Abbreviations 
AAV  Adeno-associated virus 
ADS  Buffer for isolation of neonatal rat ventricular cardiomyocytes 
Ad  Adenovirus 
AF  AlexaFluor® - fluorescent dye 
AID  Autoinhibitory domain 
AMP  Adenosine monophosphate 
ANF  Atrial-Natriuretic Factor 
ATP  Adenosine triphosphate 
BNP  Brain-Natriuretic Protein 
bp  Basepairs 
BSA  Bovine Serum-Albumin 
°C  Degree Celsius 
Ca2+  Calcium 
CDC  Cyclin-dependent kinase 
cDNA  copy-DNA 
CMV  Cytomegalovirus 
Co-IP  Co-Immunoprecipitation 
Ctrl  Control 
Da  Dalton 
ddH2O  Double distilled water 
DEPC  Diethyl pyrocarbonate 
DMEM  Dulbecco's Modified Eagle Medium 
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DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
dNTP  Desoxyribonucleotide triphosphate 
DTT  Dithiothreithol 
ECL  Enhanced Chemiluminescence 
E. coli  Escherichia coli 
EDTA  Ethylendiamine-N,N,N',N'-tetraacetate 
FBS  Fetal bovine serum 
FCS  Fetal calf serum 
Fig  Figure 
FITC  Fluorescein Isothiocyanate – fluorescent dye 
g  Gram 
GAPDH Glyceraldehyde-3-phosphate-Dehydrogenase 
GFP  Green fluorescent protein 
h  Hour 
HDAC  Histone-deacetylase 
HRP  Horseradish Peroxidase 
ifu  infectious units 
IκB  Inhibitor of kabba-B 
IONO  Ionomycin 
kb  Kilobasepairs 
KCl  Potassium chloride 
kDa  Kilodalton 
kV  Kilovolt 
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L  Liter 
λ  Lambda 
LacZ  Gene, coding for the enzyme ß-Galactosidase 
LB  Luria-broth 
M  Molar 
MgCl2  Magnesium chloride 
min  Minute 
miRNA Micro-RNA 
MW  Molecular weight 
n  Nano 
NaCl  Sodium chloride 
NCS  Newborn calf serum 
NES  Nuclear export sequence 
NFAT  Nuclear factor of activated T-Cells 
NFκB  Nuclear factor kappa-B 
NLS  Nuclear localization sequence 
NMR  Nuclear magnetic resonance 
NRVCM Neonatal rat ventricular cardiomyocytes 
OD  Optical density 
PBS  Phosphate buffered salines 
PCR  Polymerase chain reaction 
PDB  Protein database 
PE  Phenylephrine 
PFA  Paraformaldehyde 
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pH  Negative decadic logarithm of the hydronium ion concentration 
PMA  Phorbol-12-myristate-13-acetate 
Rcan1-4 Regulator of Calcineurin 1-4 
RE  Responsive element 
RNA  Ribonucleic acid 
rpm  Rounds per minute 
RT  Room temperature 
SBM  SUMO binding motif (=SIM) 
SDS  Sodium dodecyl sulfate 
SEM  Standard error of the mean 
SENP  Sentrin-specific protease 
SIM  SUMO interaction motif (=SBM) 
siRNA  Small interfering RNA 
SUMO  Small ubiquitin-related modifier 
TAC  Transverse aortic constriction 
TBS  Tris Buffered Saline 
TEMED N,N,N',N'-Tetramethylendiamin 
Tg  Transgene 
TRIS  Tris(hydroxymethyl)-aminomethan 
UV  Ultraviolet 
v/v  volume/volume 
wt  Wildtype  
w/v  weight/volume 
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